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ABSTRACT 
 
During aging, there is a decrease both in the stability of central nervous system (CNS) 
myelin once formed and in the efficiency of its repair by oligodendrocytes (OLs). To 
study CNS remyelination during aging, I used the cuprizone (a copper chelator) mouse 
model. Inclusion of cuprizone in the diet kills mature OLs and demyelinates axons in the 
rostral corpus callosum (RCC) of mice, which enabled me to characterize age-related 
changes (i.e., 2-16 months of age) in glial cell response during the recruitment (i.e., 
demyelination) and differentiation (i.e., remyelination) phases of myelin repair. I found 
that the time between 12 and 16 months of age is a critical period during which there is 
an age-related decrease in the number of OL lineage cells (Olig2Nuc+ve/GFAP-ve cells) 
in the RCC of both control mice and mice recovering from cuprizone-induced 
demyelination. My results also show there was an age-related impaired recruitment of 
progenitor cells to replace lost OLs even though there was no major age-related decrease 
in the size of the progenitor cell pool (PDGF ? R+ve/GFAP-ve, and 
Olig2Nuc+ve/PDGFαR+ve cells). However, there were cuprizone-induced increased 
numbers of astrocyte progenitor cells (Olig2Cyto+ve/PDGFαR+ve) in these same mice; 
thus PDGFαR+ve progenitor cells in mice as old as 16 months of age retain the ability to 
differentiate into astrocytes, with this fate choice occurring following cytoplasmic 
translocation of Olig2. These data reveal for the first time age-related differences in the 
differentiation of PDGFαR+ve progenitor cells into OLs and astrocytes and lead me to 
suggest that during aging there must be a transcriptional switch mechanism in the 
progenitor cell fate choice in favour of astrocytes. This may at least partially explain the 
age-related decrease in efficiency of OL myelination and remyelination. 
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I Hypothesis and Objectives  
1.1 Hypothesis  
There will be an age-related decline in the extent of remyelination by 
oligodendrocytes and in the expression of PDGF?R, MOG, Olig2, Nkx2.2, and CGT 
genes after cuprizone treatment. 
1.2 Objectives  
1.2.1 To quantify the cell density of OL lineage cells after cuprizone treatment in mice of 
different ages 
1.2.2 To quantify the expression levels of PDGFαR, MOG, Olig2, Nkx2.2 and CGT after 
cuprizone treatment in mice of different ages 
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II Literature Review 
2.1 Oligodendrogenesis 
Astrocytes, microglia, and oligodendrocytes (OLs) comprise a group of cells known 
as the glial cells (Baumann and Pham-Dinh, 2001). The majority of the cells populating 
the vertebrate nervous system are glial cells and they play an important role in neuronal 
function and development. Glial cells have the capacity to respond to changes in both 
cellular and extracellular environments in the nervous system, which is vital for the 
maintenance of normal function of the nervous system (Barres, 2008; Lepore, et al., 
2004). Improper participation of glial cells in the central nervous system (CNS) has been 
associated with brain dysfunction (Venancel, et al., 1997), and a considerable amount of 
research has been conducted to investigate the relationship between glial cells and 
pathology of the CNS (Seqal, et al., 2007; Morath, et al., 2001; Breteler, et al., 1992). 
Oligodendrocytes (OLs) are myelin forming cells in the vertebrate CNS (Baumann 
and Pham-Dinh, 2001). Most OL cell clusters are located in the white matter of the CNS 
where they initially originate from highly mitotic and migratory oligodendrocyte 
precursor cells (OPCs) (Warf, et al., 1991; Levison, et al., 2003). During development in 
later embryonic and early postnatal periods, OPCs can migrate and differentiate into 
mature OLs. Once mature, OL processes will connect and wrap around axons, eventually 
forming the myelin sheath (Inoue, et al., 1996; Connor and Menzies, 1996). This process 
is defined as myelination. Myelination is extremely complex and the mechanism of how 
OLs wrap around axons has not been fully characterized. This literature review will 
provide a basic understanding of OPC development and a general description of the OL 
lineage cells, combined with the transcriptional factors affecting OPC differentiation and 
maturation. Furthermore, the current state of knowledge on myelination and 
remyelination, as well as the key components of myelin, will also be summarized. Finally, 
demyelination diseases and animal models to study remyelination will be reviewed.  
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2.1.1 Introduction to Glia 
The two major cell constituents of the vertebrate brain are neurons (10%) and glia 
(90%) (Figure 1). Interestingly, some of these cells originate from different regions of the 
CNS. Neurons, macroglia including astrocytes, and OLs originally derive from the 
epithelial cells of the neural tube during early development (Morest and Silver, 2003). 
However, microglia are derived from the mesoderm (Kurz and Christ, 1998). Moreover, 
Schwann cells, located in the vertebrate peripheral nervous system (PNS) [that play 
similar roles to OLs in the CNS] myelinate PNS axons (Baumann and Pham-Dinh, 2001).  
The most common roles of glial cells are communication with neurons and 
maintenance of the normal functioning of the nervous system. A functional relationship 
between neurons and glial cells, such as electrical insulator role of OLs and Schwann 
cells in vertebrate nervous system has been demonstrated (Baumann and Pham-Dinh, 
2001). However, much of this knowledge is only beginning to be explored. The basic 
question to explore the function of glial cells is: How do glial cells communicate with 
neurons? Recent researches indicate that the synapse works as a key site of neuronal and 
glial interaction, in structural, biochemical and physiological aspects (Goslin and Banker, 
1990; Keyser and Pellmar, 1997; Chisari, et al., 2010). Researchers have used co-culture 
technology to show certain effects of glial cells. For example, glial cells are found to have 
an effect on synaptogenesis and synaptic function (Pfrieger and Barres, 1997).  
Moreover, glial cells including astrocytes, OLs, and Schwann cells have many ion 
channels. Glial cells express all major types of ion channels such as K+, Na+, and Ca+ 
(Chittajallu, et al., 2004). These glial cells express similar ion channels to those found in 
neurons (Baumann and Pham-Dinh, 2001); prior to this discovery neuron were 
considered to be the only cell type that produced electric impulses in the brain. However, 
recent findings suggest that OL lineage cells have the potentials to fire electrical impulses 
(Karadottir et al., 2008). Due to the various roles and electrical potential, details of 
diverse glial cells will be reviewed in the following paragraphs. 
  3 
Components of Neural Cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Components of Neural Cells. In the vertebrate nervous system, neural cells 
include neurons (10%) and glial cells (90%). Astrocytes (80%), OLs (5%) and microglia 
(10-15%) are three major cell types that maintain normal function of the CNS (Baumann 
and Pham-Dinh, 2001). In the PNS, Schwann cells rather than OLs form myelin sheaths. 
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2.1.1.1 Astrocyte 
Astrocytes are the most abundant cells in the CNS. The generation of astrocytes 
begins in late embryonic stage, and continues during neonatal and postnatal period (Wang 
and Bordey, 2008). Glial fibrillary acidic protein (GFAP) is commonly expressed in 
astrocytes and is an important marker of these cells. However, only a small number of 
astrocytes are GFAP+ve in the cortex and hippocampus (Giffard and Swanson, 2005). 
The different lineages of astrocytes suggest that they may have different functions. 
Astrocytes can also function as stem cells in the nervous system (Guillemot, 2007). 
Researchers in the last decade have indicated that GFAP-expressing cells can also 
contribute to the cell regeneration. For example, the multipotent neural stem cells in adult 
subventricular zone (SVZ) were detected to express GFAP (Baumann and Pham-Dinh, 
2001; Doetsch, et al., 1997). These stem cells were suggested to belong to the astrocyte 
family since they had GFAP-expressing properties. Moreover, in the CNS, astrocyte 
precursors can also undergo either gliogenesis or neurogenesis (Guillemot, 2007). This 
dual-directionality of cell development is not uncommon in brain formation. For example, 
OPCs can differentiate into either OLs or astrocytes during adult gliogenesis under 
different conditions (Zhao, et al., 2009). Recent finding also indicates astrocyte 
precursors have the ability to form neurons (Rivers, et al., 2008). The switch between the 
two cell types is regulated by a cascade of transcription factors (TFs) (Nicolay, et al., 
2007; Islam, et al., 2009; Dimou, et al., 2008; Tatsumi, et al., 2008).  
In the past, astrocytes were considered as “brain glue” because they lacked the 
ability to form action potentials. However, they are much more important because they 
promote neuronal maturation, neuronal survival and synapse formation during the 
development (Wang and Bordey, 2008). Commonly, an important role of astrocytes is to 
produce intermediate filaments that form the cytoskeleton in the brain, which further 
maintains the proper environment for the CNS (Pekny, et al., 2007). In addition, 
astrocytes are well-known to release growth factors including nerve growth factor (NGF), 
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brain derived neurotrophic factor (BDNF) and fibroblast growth factor (FGF). These 
factors control the maturation and survival of neuronal cells. Another important role of 
astrocytes is contributing to blood-brain barrier (BBB). Researches indicate that BBB 
tight junction proteins are up-regulated by co-culture with astrocytes (Wolburg, et al., 
2009; McQuaid, et al., 2009). It is believed that astrocytes can also maintain 
microvascular permeability in adult brain (Kaur, et al., 2008). Also, astrocytes are helpful 
to metabolism. It is well established that astrocytes metabolize glutamate into glutamine 
via glutamine synthetase (Albrecht, et al., 2007); moreover, since glutamate transporter is 
essential to the proper neuronal activity, astrocytes support the metabolic need to the 
nervous system.  
Interestingly, astrocytes and OLs keep a tight relationship in vivo and in vitro (Nait-
Oumesmar, et al., 2008; Ihrie and Alvarez-Buylla, 2008). Several pubications show a 
lineage relationship between these two types of cells (Nait-Oumesmar, et al., 2008; Ihrie 
and Alvarez-Buylla, 2008). For example, GFAP expression has been observed in 
immature OLs (Dawson, et al., 2000); co-expression of GFAP in conjunction with 
myelin-antigens has also been found in mouse brains (Dawson, et al., 2000). Also a 
dysfunction in astrocytes can induce serious disorders, such as stroke and cerebral 
ischemia (Kahle, et al., 2009; Lindsberg, et al., 2010). However, the details of the various 
roles of astrocytes are not clearly defined.  
2.1.1.2 Oligodendrocytes 
OLs can also participate in the formation of nodes of Ranvier, which play an 
important role in fast saltatory transduction (Wolswijk and Noble, 1989). Depending on 
the morphology and localization, OLs are classified into four subtypes (Baumann and 
Pham-Dinh, 2001). In most aspects, type I and type II OLs are very similar. However, 
type I OLs mainly exist in the brain and spinal cord, whereas type II OLs are only 
observed in the white matter. Compared to type I and type II OLs, type III OLs have 
larger cell bodies and fewer processes, and typically exist in the cerebral and cerebellar 
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peduncles. Type IV OLs do not have processes, but can form long myelin sheaths around 
axons directly by the cell body (Wolswijk and Noble, 1989). All four types of OLs can 
form myelin sheaths even though the number of their processes is significantly different. 
In addition, a small population of OLs in the CNS do not have the capacity to myelinate 
axons, and are termed “satellite OLs” (Ludwin, 1979). 
During OL development and maturation, many factors are necessary. These factors 
have multiple effects in OLs proliferation, differentiation, and maturation. For example, 
platelet derived growth factor (PDGF) is synthesized by both astrocytes and neurons 
during development (Kwon, 2002). PDGF is a survival factor for OPC, and is a mitogen 
for progenitors (Baumann and Pham-Dinh, 2001). Basic FGF is another mitogen for OL 
progenitors. It up-regulates the expression of platelet derived growth factor alpha receptor 
(PDGFαR), further increases the opportunity for OL progenitors to respond to PDGF 
(Redwine, et al., 1997). In addition, insulin-like growth factor (IGF) plays an important 
role in stimulating OL proliferation (Ye, et al., 2010) as well as acting as a potent survival 
factor for OLs (Ye, et al., 2010). In IGF-transgenic mice, the percentage of myelinated 
axons is significantly increased, and the myelin sheaths are thicker than control mice 
(Baumann and Pham-Dinh, 2001).  
The main function of OLs is to form myelin sheaths around axons. Significant 
research has demonstrated the important role of OLs in both development and adult CNS 
(Zeng and Jung, 2008; Schnaar and Lopez, 2009; Baumann, et al., 2001). Myelin is 
critical to saltatory transduction, thus the dysfunction of OLs can lead to myelin sheath 
destruction and to demyelinating diseases such Multiple Sclerosis (MS) but also can 
induce mental disorders (Noble, 2004; Seqal, et al., 2007). The relationship between OLs 
and myelin development will be demonstrated in subsequent chapter that will follow. 
2.1.1.3 Microglia  
Unlike macroglia cells, microglia are derived from myelomonocytic cells, which 
originate from the mesoderm of the embryo (Kurz and Christ, 1998). During 
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development, the precursors of microglia undergo proliferation, migration, and 
differentiation, finally settling in the CNS to function as gatekeepers in the CNS (Kaur, et 
al., 2010). Research indicates that amoeboid microglia are capable of working as 
phagocytes both in vivo and in vitro (Pivneva, 2008). In the normal brain, microglia 
remain in the resting stage and the cell body remains as a small soma. However, 
microglia shift to an activated state after brain injury. A fraction of the activated 
microglia consequently become phagocytic (Pivneva, 2008). Both activated microglia 
and phagocytes provide a defensive system in the brain to protect it from various injuries 
as well as diseases (Pivneva, 2008). In the past decade, many publications have reported 
on the close relationship between microglia and several disorders (Gandhi, et al., 2010; 
Gay, 2007). For example, microglia have been found to participate in all phases of MS. In 
addition, it has been revealed to be involved in age-related neurodegenerative diseases, 
notably Alzheimer’s Disease (AD). Many studies have shown s connection between 
activated microglia and amyloid plaques, which point out microglia play an important 
role in AD progression (Imbimbo, 2009; Shie, et al., 2009).  
Microglia are also essential for CNS development. For example, microglia can 
induce excess NGF-expressing neurons to undergo apoptosis, which regulates the 
quantity of neurons in the CNS (Harada and Harada, 2004). Hence, microglia play a 
crucial role in maintaining normal neuronal architecture by inducing overloaded NGF-
expressing neurons to undergo apoptosis (Mizuno, et al., 2004).  
2.1.1.4 Schwann cell 
Schwann cells perform a similar role in the PNS to that of OLs in the CNS. Schwann 
cells originate from Schwann cell precursors (Woodhoo and Sommer, 2008). The 
precursors are derived from neural crest cells. During vertebrate development, the 
precursor cells migrate and differentiate into mature Schwann cells that consequently 
myelinate axons in the PNS. Interestingly, myelinating Schwann cells can only myelinate 
axons with a 1:1 ratio. Hence, one Schwann cell only myelinates one axon (Baumann and 
  8 
Pham-Dinh, 2001). The underlying mechanisms by which Schwann cells myelinate axons 
are not clear, but OLs and Schwann cells are proposed to share some factors involved in 
myelination (Ogata, et al., 2006; Rajasekharan, 2008).  
2.1.2 Stepwise development of oligodendrocyte lineage cells  
Improvements in immunohistochemical techniques combined with developments in 
molecular biology have widely expanded our knowledge regarding OL development and 
lineage. Observations from in vivo and in vitro experiments show a linear progression of 
stages during OL development (Woodruff, et al., 2001; Zhang, 2001; Miller, 2002; Raff, 
et al., 1984). The identification of various cellular markers that determine cell fate and 
maturation also reveal a stepwise development of oligodendrocyte lineage cells (Pfeiffer, 
et al., 1993; Raff, 1989; Baumann and Pham-Dinh, 2001; Le Bras, et al., 2005).  
2.1.2.1 Stepwise oligodendrogenesis  
Details of OL development and maturation have been described in many models, 
and researchers are working towards a system that represents all OL lineage cells. 
However, it is unlikely that all details of OL development will be the same in different 
regions of the CNS. Cells are generated at different times due to anatomical variations in 
different regions. For example, the majority of the white matter in the brain is centrally 
located while most white matter in the spinal cord is located in the periphery. Despite the 
differences mentioned above, all glial cells share significant similarities during their 
generation. First, most cells in the CNS including neurons originate from the ventricular 
zone (VZ) in the embryonic stage (Hardy and Friedrich, 1996; Vallstedt, et al., 2005; Le 
Bras, et al., 2005), and a variety of transcriptional factors contribute to their 
developmental progress (Nicolay, et al., 2007). Immature OLs, which eventually become 
mature OLs, are located mainly in ventral regions of the neuraxis (Hardy and Friedrich, 
1996). The fact that glial cells and neurons originate from the same precursors is well 
known; however, when the stem cells begin to differentiate and how this process is 
controlled remain the subject of ongoing research.  
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In general, OL development throughout the CNS follows a similar pattern. After 
neuronal stem cells divide into different precursor cells, the OL lineage division become 
A2B5+ve bipolar OPCs during the late embryonic phase (Hardy and Friedrich, 1996; 
Vallstedt, et al., 2005), which can consequently differentiate into both OLs and astrocytes 
(Raff, et al., 1984). OPCs migrate extensively throughout the CNS. This process is highly 
regulated by a large number of important molecules (Byravan, et al., 1994; Dai, et al., 
1997; Kuhn, et al., 1999; Goldberg, et al., 2004). After their migration and proliferation 
in the CNS, progenitors grow fiber tracts that consequently form white matter, and 
eventually transform into O4+ve pre-myelinating OLs (Pfeiffer, et al., 1993). At this 
stage, they lose their mitogens, such as PDGFα, and thus stop proliferating. At the same 
time, these OPCs begin to differentiate into myelin basic protein (MBP)+ ve mature OLs 
(Figure 2) (Baumann and Pham-Dinh, 2001). Although they follow the same 
developmental patterns, variations exist between OL lineages in different regions in the 
brain, even in various lineages in the forebrain (Vallstedt, et al., 2005; Nait-Oumesmar, et 
al., 2008).  
Some OLs and astrocytes share the same progenitors in the embryonic stage, 
particularly when they are generated from the SVZ (Nait-Oumesmar, et al., 2008; Ihrie 
and Alvarez-Buylla, 2008). Studies indicate OLs in the Ventricular Zone (VZ) are 
generated during the first week of life in rodents, which is consistent with astrocytes 
(Kagawa, 2001; Baumann and Pham-Dinh, 2001 ). The earliest cells that express early 
markers of OLs have been found in the ventral forebrain. The progenitors begin to 
express DM-20 (Dickinson, et al., 1996) and PDGFαR (Pringle and Richardson, 1993), 
which are markers of OPCs. Interestingly, markers for DM-20+ve and PDGFαR+ve do 
not appear in the same cell, though the relationship between these two types of cell 
markers is still unclear; these two cell lineages are proposed to divide into two classes of 
OLs (Pringle and Richardson, 1993, 2000; Spassky, et al., 2000).  
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Both DM-20+ve and PDGFαR+ve cells appear in dorsal rather than ventral locations 
(Warf, et al., 1991; Pringle and Richardson, 1993; Fok-Seang and Miller, 1994; Tekki-
Kessaris, et al., 2001). These findings are further confirmed by observations that OPCs 
migrate extensively in a ventral to dorsal direction during the late embryonic period. 
During this period, SVZ cells do not express early markers of both OLs and astrocytes 
within the SVZ; instead, they begin to express early antigens for glial cells such as 
PDGFαR and NG2 after they exit the SVZ (Zhao, et al., 2009). This dorsolateral SVZ 
provides cells that travel to the cortex, white matter, striatum, and olfactory bulb for both 
OL and astrocyte generation (Young, et al., 2007).  
OPCs are generated from the SVZ at the base of the third ventricle and migrate 
along the optic nerves (Sugimoto, et al., 2001). However, this cell type shows a 
bipotential nature. The OPCs can develop into OLs or astrocytes due to the existence of 
the optic nerve and other factors (Calver, et al., 1998; Gross, et al., 1996). Interestingly, 
OL development is not exactly the same even in the forebrain. For example, glial cell 
development in the optic nerves is delayed compared to OLs in the white matter. Also, 
these two cell types do not share the same progenitors. Optic nerve astrocytes appear to 
be more intrinsic, and likely arise from the radial glial cells that originate from the optic 
nerve neuroepithelium (Sugimoto, et al., 2001). 
In addition to the forebrain, another area that holds a large area of white matter is the 
cerebellum. The cerebellum contains OLs as well as astrocytes. Both these glial cells 
arise from the base of the cerebellum and share the same progenitor (Levine, et al., 1993). 
During prenatal development, the progenitors migrate through the white matter tracts and 
form a giant area of white matter in radial directions (Levine, et al., 1993). Concurrently, 
some progenitors begin to express early markers, such as NG2 for OLs and GFAP for 
astrocytes. In addition, OL development in the spinal cord is highly dependent on 
dorsoventral patterning. Cells in the motor neuron progenitor domain (pMN) express the 
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basic helix-loop-helix (bHLH) transcriptional factor Olig2 (Fu, et al., 2002; Novitch, et 
al., 2001). 
Unfortunately, the mechanism that determines whether neuronal progenitor OPCs 
develop into OLs or astrocytes is still unclear. However, current research suggests a 
series of transcriptional factors may be involved in the process. For instance, results from 
different laboratories suggest expression of Olig2 switches the fate of progenitors and 
triggers the development of the OL lineage cells rather than astrocytes (Islam, et al., 2009; 
Dimou, et al., 2008; Tatsumi, et al., 2008). Information about these TFs will be discussed 
in a later section (Section 2.1.4).  
2.1.2.2 Oligodendrogenesis in the adult CNS 
Research in the past several decades suggests neurogenesis also occurs and is 
important for the normal development of the adult CNS (Fujimoto, et al., 2009; Lee and 
Son, 2009; Ahlenius, et al., 2009). Studies have demonstrated both neuron and glial cell 
proliferation in adult brain, and have broadened knowledge in this area.  
Studies conducted by different research groups suggest glial cells may arise from 
either existing proliferating cells or from neuronal progenitors. However, increasing 
evidence support the latter theory (Ahlgren, et al., 1997; Kiernan and Ffrench-Constant, 
1993; Almazan and McKay, 1992). Progenitors isolated directly from the adult CNS 
express several markers such A2B5, O4, and GFAP. In addition, an in vivo study found 
NG2 chondroitin sulfate proteoglycan positive cells in adult brain (Baracskay, et al., 2007; 
Gard and Pfeiffer, 1990; McCombe, 2008). Though NG2 is found during 
oligodendrogenesis, it is now unclear whether NG2 is a marker for a single type or 
multiple types of glial cells. Many NG2+ve cells contact the node of Ranvier in white 
matter and synapses in gray matter, suggesting they may play a role in the maintenance of 
stable glial populations (Butt, et al., 2004).  
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        Stepwise oligodendrocyte development 
 
 
 
 
   Figure 2. Stepwise oligodendrocyte development. OLs originate from bipolar 
progenitors. During their development, OPCs undergo A2B5+, NG2+, and O4+ stages 
before eventually becoming mature OLs. MBP and MOG are two major markers for OL 
maturation (taken from Zhang, 2001 with permission).   
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Moreover, studies in rodents and human indicate NG2 exists in adult brains in 
various pathologies, suggesting a small population of neuronal cells in adult brains may 
indeed maintain the ability to proliferate (Zhao, 2009; Komitova, et al., 2009).  
2.1.3 Oligodendrocyte precursor cells  
During development of the CNS, the mechanism determining the fate of the 
precursors of both neurons and glial cells is unknown. The gene that encodes ‘glial cells 
missing’ (gcm) protein induces the stem cells to lose their glial cell properties and switch 
into neurons (Ho, et al., 2009; Soustelle and Giangrande, 2007; Soustelle, et al., 2008). 
As mentioned above, both neurons and glial cells in the mammalian cortex originate from 
proliferating neuroepithelial cells in the VZ and SVZ. The growth factors and 
transcriptional factors circulating in the SVZ influence cell survival and are involved in 
proliferation and differentiation of the neuroepithelial cells. However, the focus on this 
project is on the OPCs arising from the multi-potential stem cells.  
2.1.3.1 Development of OPCs during embryonic stages 
OPCs originate from specific regions in the CNS. Two distinguishable populations 
of OPCs in the CNS come from the VZ and SVZ, respectively (Juliet, et al., 2009; 
McMahon and McDermott, 2001; Nait-Oumesmar, et al., 2008). Although most OLs 
locate in the white matter, OPCs originate from the VZ and SVZ at a very early stage in 
the embryo.  
The spinal cord is one of the systems studied in which OPCs have originated from 
VZ at early embryo stages. This system has been extensively studied and is well 
understood. In the spinal cord, the OPCs initially arise in the neural tube. At embryonic 
day 14 (E14) in rodents, OPCs begin to migrate in the ventral to dorsal direction and have 
the capacity to differentiate into OLs in the ventral region of the spinal cord (Timsit, et al., 
1995; Hardy and Friedrich, 1996). As mentioned before, two major markers of OPCs, 
DM-20 and PDGFαR, are never expressed together. However, either DM-20 positive or 
PDGFαR positive OPCs can eventually become mature OLs in the spinal cord.  
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The initial localization of OPCs in the ventral regions of the neural tube does not 
determine the localization of mature OLs. Mature OLs are localized not only in the spinal 
cord but also in the midbrain and forebrain (Ono, et al., 2009; Fu, et al., 2003). In 
addition, oligodendrogenesis occurs in similar regions in the vertebrate CNS across 
different species including human, mouse, and chicken (Ono, et al., 1997).  
In addition to the OPCs in the VZ, another population of OPCs arises from the SVZ. 
The SVZ is a matrix that first appears during the later stages of embryonic development 
(Doetsch, et al., 1997). It begins its extension five days after conception, at the peak of 
oligodendrogenesis (Luskin, 1988; Price and Thurlow, 1988). Although the majority of 
OLs come from homogeneous progeny, both OLs and astrocytes can also originate from 
precursor cells in the SVZ. In the SVZ of adult brain, some cells can even grow neurons 
and other glial cells (Rivers, et al. 2008). While some have assumed all cells in this 
structure are radial cells (Rakic, 1995), several studies using various techniques suggest 
cells diffuse postnatally and even during embryonic development. A large population of 
OLs arises from the SVZ in the cerebrum and optic nerves of newborn rodents 
(Fernandez, et al., 2004; Levine, et al., 1993). The OPCs migrate and proliferate quickly 
and do not concurrently differentiate, which helps to maintain the correct function of 
mature OLs.  
2.1.3.2 OPCs in adult CNS 
OLs have the ability to myelinate axons, which is critical for proper repair of the 
CNS. In the human brain, OPCs can be recruited continuously and further differentiate 
into mature OLs and myelinate axons into the fifth decade of life (Bartzokis, 2004; 
Bartzokis, et al., 2004). Thus, adult OPCs play important roles not only with respect to 
injury repair but also for normal function of myelination.  
Recent research has demonstrated not all OPCs differentiate during CNS 
development (Figure 3). Some OPCs in the adult CNS still have the ability to 
differentiate. Differences between the OPC differentiation during development and in the 
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adult CNS include antigenic phenotype and proliferation rate. In the adult CNS, the 
activity of OPCs is relatively low due to the lower expression level of mitogens, which 
limit the proliferation rate. Under normal conditions, adult OPCs are inactive, but once 
mature OLs die or undergo apoptosis, the OPCs are rapidly recruited and consequently 
undergo differentiation and maturation.  
2.1.4 Transcriptional control of oligodendrogenesis 
During the formation of the myelin sheath, OLs undergo complicated regulatory 
mechanisms that are not fully understood. The specification and maturation of OLs are, 
for the most part regulated by multiple transcriptional factors (TFs). The majority of these 
TFs are regulated by signaling pathways such as sonic hedgehog (Shh), bone 
morphogenetic protein (BMP), and Notch (Nicolay, et al., 2007). Interestingly, these 
signaling pathways and TFs play multiple roles in OLs regulation, as either inductive, 
inhibitory, or permissive factors (Figure 4). 
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          Adult neural genesis in the CNS 
 
 
 
 
 
 
Figure 3. Adult neural genesis in the CNS. Neural stem cells exist in the adult brain, 
and retain the ability to differentiate into either neurons or glial cells, including 
astrocytes and OLs (taken from Galderisi, et al., 2003 with permission).  
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Basic transcriptional network of OL development 
 
 
 
 
 
 
 
Figure 4. Basic transcriptional network of OL development. Multiple TFs control 
OL development. Expression levels of TFs at different times determine the cell fate and 
further regulate OL maturation (taken from Nicolay, et al., 2007 with permission).  
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2.1.4.1 Inductive factors to OLs specification 
PDGFαR is essential during the early development of OLs in the pMN domain, 
which is characterized by the bHLH oligodendrocyte specific TFs, Olig1 and Olig2 (Lu, 
et al., 2000). However, in the absence of Olig2, PDGFαR is expressed at a lower level 
with no expression in the spinal cord (Lu, et al. 2002). Expression of Olig1 and Olig2 are 
affected by the Shh signaling pathway, which is concentration dependent (Lu, et al., 
2000). Recent research demonstrates the consistent role of the Shh signaling pathway 
throughout CNS development. For example, Shh mutant mice lack Olig1, Olig2, and 
PDGFαR expression (Lu, et al., 2000; Alberta, et al., 2001). Conversely, higher 
expression levels of Olig2 and PDGFαR are found when a Shh-expressing retrovirus is 
injected into the embryo (Nery, et al., 2001). However, the function of Shh varies in 
different areas throughout the CNS. Although Olig2 plays a critical role in the induction 
of PDGFαR expression in the spinal cord, PDGFαR is still expressed in the forebrain and 
hindbrain when Olig2 is absent (Lu, et al., 2000). Interestingly, PDGFαR expression is 
absent in Olig1/Olig2 knockout mice (Lu, et al., 2000; Alberta, et al., 2001).  
2.1.4.2 Signaling pathways involved in development of OLs  
Three additional TFs—Nkx2.2, Pax6, and Irx3—together with Olig2 define the 
boundaries of the pMN domain (Zhou, et al., 2000; Briscoe, et al., 2000). Specifically, 
Nkx2.2 and Pax6 demarcate the ventral pMN, whereas Olig2 and Irx3 define the dorsal 
pMN (Zhou, et al., 2000; Briscoe, et al., 2000; Novitch, et al., 2001). Because the TFs 
control the boundaries of the pMN domain, the expression of particular TFs in certain 
areas modulates the temporal development. For example, a one-day delay in PDGFαR 
expression has been discovered in Pax6 deficient mice (Briscoe, et al., 2000). In addition, 
Nkx2.2-repressed Olig2 expression has been demonstrated in early development (Zhou, 
et al., 2001; Novitch, et al., 2001). Furthermore, progress may be delayed by Irx3-
suppressed Olig2 expression though the precise function of Irx3 in OL development has 
not yet been determined (Novitch, et al., 2001).  
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Unlike Shh signaling pathways that promote differentiation of OL lineage cells, 
BMP regulates TFs that suspend OL development (Vallstedt, et al., 2005). Recent 
research indicates blocked BMP signaling results in an expansion of O4 positive cells in 
the embryo, suggesting the conversion of OL lineage cells (Mabie, et al., 1999). Indeed, 
BMP suppress the expression of Olig2 in early development by enhancing Irx3 
expression (Meyer and Roelink, 2003). In addition, BMP signaling may prevent OL 
maturation by enhancing Id2 and Id4 expression. Recent research demonstrates over-
expression of Id2 and Id4 can prevent OPC differentiation into the GalC+ve stage of OL 
maturation (Samanta and Kessler, 2004; Wang, et al., 2001; Kondo and Raff, 2000). 
Collectively, BMP signaling inhibits OL development.  
Another essential signaling pathway for OL development is Notch signaling, which 
controls the neural-glial switch. Research indicates Notch represses the expression of 
Ngn1/2, which is necessary to determine the fate of OPCs. Notch signaling offers the 
environment for OLs specification (Zhou, et al., 2001). Aside from its contribution in the 
specification of OL lineage cells, Notch signaling also prevents the maturation of OL 
lineage cells. Over-expression of Notch signaling has been associated with the 
accumulation of OPCs (Park and Appel, 2003). Furthermore, OPCs fail to differentiate 
when Hes5, the downstream target of Notch, is over-expressed (Deneen, et al., 2006; 
Wang, et al., 1998). On the other hand, a deficiency of Notch results in a higher 
expression level of MBP and proteolipid protein (PLP), markers of differentiating and 
mature OLs, in different regions in the brain (Park and Appel, 2003; Genoud, et al., 
2002).  
2.1.4.3 TFs in OLs maturation 
As discussed above, Shh and Notch signaling directly or indirectly stimulates the 
specification of OPCs. Conversely, BMP only negatively regulates OL specification. 
Under the control of these signaling pathways, TFs undergo a complex mechanism to 
regulate oligodendrogenesis. For example, Irx3 and Nkx2.2 affect the normal expression 
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level of Olig2 that is necessary for early OL specification. Hes5 can bind Sox10 and/or 
Mash1 and thus inhibit the maturation of OLs (Liu, et al., 2006). Hes5 can also bind to 
the MBP promoter without affecting its activity, which suggests an indirect regulation of 
OL maturation (Liu, et al., 2006). Olig1 promotes OL maturation via Sox10 and Zfp488. 
In the absence of Olig1, Zfp488 does not express in the forebrain, cerebellum, and spinal 
cord, which consequently leads to a reduction of MBP (Wang, et al., 2006). Sox17 is 
another important TF for OL maturation that can decrease cell proliferation while 
enhancing MBP transcription (Sohn, et al., 2006). Nkx6.2 is required during myelination 
and has similar expression profile to MBP and PLP, which are the main components of 
myelin sheaths (Awatramani, et al., 1997). Another important TF that regulates OL 
development is MyTI. When MyTI is induced, OL maturation is enhanced (Nielsen, et al., 
2004). Conversely, the truncation of MyTI results in a decline in OL differentiation 
(Nielsen, et al., 2004). Additionally the homeobox (Hox) TF family may also regulate 
myelination in the CNS. Hoxd1 can bind to the promoter region of the myelin 
oligodendrocyte glycoprotein (MOG) gene (Booth, et al., 2007), which plays a critical 
role in the final step of myelin sheath formation. Hoxd1 belongs to the Hox gene family, 
which is critical during embryo development. The expression profiles of Hoxa2, Hoxb3, 
and Hoxb4 during OL development have been recently published (Hao, et al., 1999; 
Nicolay, et al., 2004; Nicolay, et al., 2004b).  
In addition to TFs, thyroid hormone (TH) also plays an important role in OL 
development. TH receptors are identified in both OPCs and OLs (Fernandez, et al., 2004; 
Gao, et al., 1998; Barres, et al., 1994). In fact, murine hypothyroidism facilitates the 
proliferation of NG2-expressing cells in the SVZ. Interestingly, TH has different effects 
on the development of OLs. For example, purified murine OPCs from E7 stop dividing 
and rapidly begin to differentiate when exposed to T3, while those from E18 remain in 
cell cycle in the presence of T3 (Gao, et al., 1998). Hence, TH activates the effector to 
influence stepwise OL maturation rather than indirectly triggering cell differentiation.  
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2.2 Introduction to myelination and remyelination 
The main function of OLs is to generate the myelin sheath that insulate axons in the 
CNS; Schwann cells perform a similar role in the PNS. Myelin sheath is a fatty layer that 
insulates axons and facilitates saltatory conduction within neurons (Bauer, et al., 2009; 
Collarini, et al., 1991; Lopes-Cardozo, et al., 1989). Using the plastic coat around 
electrical wires as a comparison, myelin sheaths are in contrast composed of living tissue 
that need to be produced constantly throughout the lifespan by special myelinating 
cells—OLs in the CNS and Schwann cells in the PNS.  
OLs and the axons around which the OLs form myelin sheaths exist 
interdependently. The proliferation and differentiation of myelinating OLs are regulated 
by a variety of signaling pathways. Also, the growth of myelin sheaths is determined by 
normal function and integrity of the axons (Kagawa, et al., 1994; Readhead, et al., 1994). 
It is important to maintain axons in the CNS for normal OL function. In some cases, loss 
of axons results in degeneration of the OLs and eventually leads to pathological 
abnormalities (Anderson, et al., 1998). Interestingly, if their structure is degenerated, 
myelin sheaths in the adult CNS can be reformed by myelinating OLs through the process 
of remyelination (Mi, et al., 2008; Gallo and Armstrong, 2008; Nait-Oumesmar, et al., 
2008).   
2.2.1 Myelin 
Myelin is an essential component of white matter in the vertebrate CNS. The main 
components of myelin are lipids and proteins that are generally found only in OLs 
(Bronstein, et al., 1997; Coffey and McDermott, 1997). The lipids provide both the 
structure for the myelin sheaths as well as the ability to insulate the axons; the myelin 
proteins maintain the normal function of OLs during development and further assist 
myelin sheath formation. With recent knowledge regarding the localization and function 
of myelin proteins, details of OL development and myelination are becoming better 
understood.  
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The major lipids composing myelin are cholesterol, phospholipids, and glycolipids 
(Agrawal, et al., 1982; Tetzloff and Bizzozero, 1998; Baumann and Pham-Dinh, 2001). 
Most cholesterol is produced by OLs in the brain. It helps to compact myelin sheath 
formation due to its high hydrophobicity (Rosetti, et al., 2008). Cholesterol is also 
required during axon regeneration (Chakraborty, et al., 1997). In addition, the synthesis 
of cholesterol is critical to myelination since an abnormal synthesis of cholesterol is 
strongly associated with neurological diseases such as Alzheimer’s disease.  
Another myelin component that has been widely studied is the glycosphingolipids, 
particularly galactocerebrosides (GalC) and its derivatives, sulphatides, which are used as 
markers following immunohistochemical analysis to identify OLs (Dupree, et al., 1998; 
Matsubayashi, et al., 2009). GalC is one of the early markers that reproducibly presents 
itself on the processes of mature OLs (Matsubayashi, et al., 2009). Generally, GalC 
appears when pre-mature OLs lose the expression of A2B5 (Baumann and Pham-Dinh, 
2001). Ceramide galactosyl transferase (CGT), the enzyme that catalyzes the final step of 
GalC synthesis, is used to test the function of GalC in OL development. Without the 
presence of GalC, myelin is not synthesized correctly. For example, in CGT knockout 
mice, saltatory conduction is blocked in the CNS, though OLs can still form myelin 
sheaths (Coetzee, et al., 1996; Bosio, et al., 1996). Furthermore, most CGT knockout 
mice die at the end of myelination period (Dupree, et al., 1998). Interestingly, under 
electron microscopy, the abnormalities have only been shown in the CNS and not the 
PNS, indicating GalC is more critical to the proper myelin formation and axon-OL 
interaction in the CNS (Dupree, et al., 1998).  
As mentioned above, most myelin proteins are found only in myelin. The major 
components of myelin in the CNS are MBP and PLP. Myelin also contains other 
constituents including myelin associated glycoprotein (MAG), MOG, and 2’,3’-cyclic 
nucleotide-3’-phosphodiesterase (CNP) (Tetzloff and Bizzozero, 1998; Baumann and 
Pham-Dinh, 2001; Walsh and Murray, 1998). (Figure 5) 
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Structure of the myelin sheath 
 
 
 
 
 
 
Figure 5. Structure of the myelin sheath. Within the myelin sheath, myelin proteins 
assist the formation of compact multi-layers. MOG, MBP, MAG, and PLP express 
during the later stages of myelination and act as markers of mature OLs (adapted from 
Verkharatsky and Butt, 2007).  
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PLP, the most abundant myelin protein in the CNS, constitutes up to 50% of myelin 
(Pham-Dinh, et al., 1991). PLP has been studied for over 50 years, and its properties are 
well understood. In the CNS, both PLP and its isoform DM-20 are synthesized by OLs. A 
variety of functions of PLP have been proposed, such as axon-OL interaction, membrane 
adhesion, compact myelin sheath formation, and maintenance of axons. PLP knockout 
mice lose the ability to condense myelin sheaths as well as to maintain normal axonal 
activity (Klugmann, et al., 1997). In addition, research suggests PLP expression directly 
enhances the proliferation of OLs. As the major myelin proteins, PLP and DM-20 are 
also candidates for the study of autoimmune attack in demyelination diseases such as 
multiple sclerosis (MS) (Olson and Miller, 2009; Kooi, et al., 2009). In the experimental 
autoimmune encephalomyelitis (EAE) model that mimics the pathology of MS, T-cells 
respond to PLP epitopes in the cytoplasm. Similarly, MS patients show increased levels 
of T-cells in their blood (Wang, et al., 2006). Thus, PLP plays important roles in both 
myelin formation and maintenance of normal axonal function.  
MBP is the second most abundant protein in the CNS, and comprises 30% of the 
myelin proteins (Klugmann, et al., 1997). MBP has been found in both the CNS and PNS, 
and performs as a key factor in the fusion of the cytoplasmic interface between myelin 
layers. Research suggests MBP null mice lack compact myelin sheaths in the CNS; the 
MBP mutant rat shows a similar result (Kirschner and Ganser, 1980; Martini, et al. 1995). 
Multiple MBP isoforms have been confirmed in OLs and myelin sheaths, with humans 
and mice having 4 and 5 isoforms, respectively (Kimura, et al., 1998; Kimura, et al., 
1989). The main difference between these isoforms is the expression of exon 2 (Kimura, 
et al., 1989). Research indicates these isoforms are individually regulated and differently 
located, suggesting the proposed functions may be different (Kimura, et al., 1998). In 
addition, MBP mediates the interactions with actin and tubulin. Studies suggest MBP 
causes G-actin polymerization, which further contributes to cytoskeleton formation in 
OLs (Boggs and Rangaraj, 2000).  
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MAG is one of the major components of glycoprotein in the CNS. MAG has both a 
membrane-spanning domain and extracellular region (Baumann and Pham-Dinh, 2001). 
MAG is proposed to interact with neural cell adhesion molecules (NCAM) during 
myelination. The functions of MAG have been studied in multiple knockout mice. 
Interestingly, the formation of myelin is almost normal in MAG-deficient mice but with a 
notable delay in myelin sheath compaction (Yin, et al., 1998). MAG may also help OLs 
distinguish between myelinated and unmyelinated axons (Schachner and Bartsch, 2000). 
Moreover, MAG has been considered a key factor during the initial step of myelination. 
Indeed, both in vivo and in vitro studies demonstrate the association between MAG and 
axon-OL interaction. Another potential role of MAG is the inhibition of neurite 
outgrowths. For example, the abundant soluble extracellular domain of MAG released 
from myelin can inhibit the regeneration of axons (McKerracher, et al., 1994).  
MOG is a glycoprotein that is found only within OLs in the CNS, and is a surface 
marker of mature OLs. MOG locates on the surface of membrane, and further appears on 
the most outside of the myelin lamellaes (Brunner, et al., 1989). Thus, MOG is widely 
used as the final marker to indicate the maturation of OLs as it presents only in the late 
stages of myelination. Currently, MOG is considered as an adhesion molecule or cellular 
receptor that is involved in the completion and compaction of myelin sheaths (Coffey and 
McDemott, 1997). However, the precise function of MOG is unknown.  
CNP is specific to both OLs in the CNS and Schwann cells in the PNS. It is 
expressed in the early stages of OL development. Two isoforms of CNP are distinguished: 
CNP1 and CNP2 (Walsh and Murray, 1998). Although the function of this enzyme has 
not been revealed, it has been suggested that CNP can regulate myelination. Recent 
studies indicate the dysfunction of CNP in the CNS can lead to unusual expansion of OL 
membranes (Gravel, et al., 1996; Nave and Trapp, 2008).  
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2.2.2 Myelination in developing CNS 
Myelination of axons in the developing CNS includes a series of steps during which 
multiple TFs and surface molecules are required. Compared to Schwann cells that can 
only myelinate axons at a 1:1 ratio, mature OLs can myelinate multiple axons. On 
average, one OL can myelinate more than ten individual axons. However, multiple 
myelin sheaths around the same axon are rarely produced by an individual OL (Petters, et 
al., 1991). Each myelin sheath is compacted with lamellae that extend from OL processes 
via cytoplasm that communicates with the OL cell body. In terms of the volume of 
myelin, OLs are the largest cells in the body. Once they become mature, OLs will contact 
and wrap the candidate axons, and consequently form the fatty myelin layers or lamellae. 
These processes are easily observed in the transverse section (Baumann and Pham-Dinh, 
2001) (Figure 6).  
The precise mechanisms involved in myelination have not yet been resolved. 
However, the entire process of myelination can be divided into three phases (Baumann 
and Pham-Dinh, 2001). In the first phase, OLs recognize candidate axons that require a 
myelin sheath. The pre-myelinating OLs can contact several axons, but only those 
beyond a critical diameter will be myelinated. In the second phase, myelinating OLs will 
wrap around the axons. Both adhesion and longitudinal outgrowths will be processed in 
this step. Although these adhesion molecules have not been identified, cell surface 
molecules such as MAG and NCAM likely play essential roles during this stage (Yin, et 
al., 1998). After the initial outgrowth of myelin around the axon, subsequent steps occur 
in the third phase. First, non-compacted myelin lamellae interact within each other, and 
subsequently form compact myelin sheaths with multi-layers. Research indicates this step 
depends upon PLP and MBP. Without the presence of PLP, axon degeneration occurs, 
indicating the critical function of PLP during myelin sheath formation (Klugmann, et al., 
1997; Kooi, et al., 2009). In addition, MBP-deficit mice lack a compact myelin structure 
(Kirschner and Ganser, 1980; Martini, et al., 1995). As discussed above, myelin lipids 
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and proteins regulate correct special and temporal assembly of compact myelin sheaths 
during myelination. 
The assembly of myelin sheaths is accompanied by formation of a bilayer of 
plasmalemma, maturation of axon-glial junctions, as well as arrangement of nodes of 
Ranvier (Schnaar and Lopez, 2009). In the CNS, nodes of Ranvier are assembled based 
on clusters of Na+ (Zeng and Jung, 2008). Since Na+ channels are present throughout the 
axons, the OL processes can recognize the signal and “grow” between Na+ channel 
clusters, further from the unsheathed regions defined as the nodes of Ranvier. As myelin 
is found extensively in the vertebrate nervous system, this element is considered to be 
important in higher nervous function (Zeng and Jung, 2008). Indeed, both the high 
electrical resistance and low capacitance of myelin promotes signal impulse jumps from 
node to node. Rapid saltatory conduction results in faster signaling from one segment to 
another within the internodal myelin sheaths.  
2.2.3 Remyelination after demyelination 
In some cases, demyelination can occur in the vertebrate nervous system, due to 
either natural or pathological reasons (e.g. MS). However, after injury or degeneration of 
white matter, adult neural stem cells are recruited, and will further migrate and 
differentiate into mature OLs. The “newborn” OLs help to rebuild the myelin structures 
that support rapid signal transduction through axons. As opposed to myelination, which 
starts during late embryonic and early postnatal stages, this progress is termed 
“remyelination”. Most genes that regulate either myelination or remyelination are the 
same (Franklin, 2008), with a few key genes such as olig2 determining the fate of the 
OPCs.  
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Formation of myelin 
 
 
 
 
 
Figure 6. Formation of myelin. Myelin is a fatty layer around the axon. (A) The 
processes of an OL wrapping then insulating an axon. (B) Each OL can myelinate 
several axons. Myelin sheaths are part of the processes of OLs (adapted from 
Verkharatsky and Butt, 2007).  
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Once demyelination occurs, the system undergoes spontaneous recovery. However, 
knowledge on this spontaneous remyelination is very limited as it even occurs under 
normal conditions. Recent research indicates neural genesis can take place following the 
death of functional cells in adult brain (Bartzokis, 2004; Bartzokis, et al., 2004). The 
main sources for adult neural genesis are the hippocampus, SVZ, and olfactory bulb (OB) 
(McMahon and McDermott, 2001; Nait-Oumesmar, et al., 2008). In addition, 
remyelination mechanisms may be similar to myelination during development, which 
itself is not entirely understood. However, remyelination fails in demyelination diseases 
such as MS, suggesting unknown factors can modify the process.  
Research demonstrates over-expression of TFs such as Olig1, Olig2, Sox10, and 
Notch signaling can promote OL specification and differentiation (reviewed in Nicolay, 
et al., 2007), suggesting the decline of these factors may reduce maturation of OLs in 
adult CNS. Indeed, researchers using animal models have illustrated the stepwise 
generation of adult OPCs, which strongly demonstrates the possibility for remyelination 
in the adult CNS (Bartzokis, 2004; Bartzokis, et al., 2004).  
 
2.3 Diseases related to demyelination 
Due to the consequent abnormal behaviors and cognitive damage, the pathology of 
demyelination diseases in humans has become one of the most popular areas of scientific 
investigation. Diseases such as MS, stroke, Alzheimer’s disease (AD) and schizophrenia 
are strongly related to demyelinated lesions. Various animal models have been developed 
to study these diseases (see below).  
2.3.1 Multiple Sclerosis 
The corpus callosum (CC) is the major white matter tract that crosses the 
homologous hemispheres in the vertebrate brain (Connor, 2004; Noble, 2004). It consists 
of approximately 200 million interhemispheric fibers, most of which connect homologous 
regions of the cerebral hemispheres (Biegon and Eberling, 1994). The CC acts as an 
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essential bridge that provides the connection between these regions, and integrates 
sensory, motor, and cognitive information (Steinman, 2001). Since an impaired CC may 
have less fiber and reduced functional connectivity between the hemispheres, differences 
in the size of the corpus callosum may lead to distinct cognitive consequences (Gootjes, 
et al., 2006).  
MS is a chronic inflammatory demyelination disease in the CNS. Recognized more 
than 100 years ago, it is the most widely investigated demyelination disease in the world. 
Massive demyelination has been identified in the MS brain, followed by extreme 
macrophage activation. However, the pathology of MS has not been clarified. One clue is 
the massive demyelinated lesions found in CNS white matter, particularly in the CC 
(Steinman, 2001). Many animal models have been created to study demyelination and 
remyelination. In these models, viruses, toxins, or myelin protein antigens are introduced 
to mimic demyelination and inflammation (Arnett, et al., 2004; Doucette, et al., 2010; 
Franklin, et al., 2002). Further investigations have also revealed differences of OL 
lineage cells in treated animals compared to controls (Rist and Franklin, 2008; Sim, et al., 
2002).  
As mentioned above, OLs must play an important role in the pathogenesis of MS 
due to the correlation between MS and white matter dysfunction. Recent research 
indicates OPCs are typically present in demyelination lesions but do not undergo normal 
maturation, suggesting the inability of OPCs to differentiate (Raine, 1997). In addition, 
human endogenous retrovirus glycoprotein-mediated induction of redox reactants can 
cause OL death, which may be another factor in MS pathology (Antony, et al., 2004). 
Moreover, the apoptotic death of OLs is now being considered as a key step in the 
initiation of MS development, which may progress to autoimmune attack (Artemiadis and 
Anagnostouli, 2010). A strong relationship between OLs and MS exists although the 
actual mechanisms that determine the initiation and progression of MS are not clear.  
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2.3.2 Stroke   
Stroke is a rapidly developing disease in the CNS due to the disturbance of blood 
supply. Both ischemia and hemorrhage can induce stroke in human brain. Consequently, 
the affected regions lose normal function (Chiti, et al., 2009). With high metabolic 
activities, OLs are particularly vulnerable to ischemia as decline of mitochondrial 
function induces OLs to undergo apoptosis. In addition, death of OLs can lead to axonal 
degeneration (Chen, et al., 2008); subsequent disruptions of the nerve fibers may cause 
severe abnormal behaviors (Chen, et al., 2008). A recent study found OL dysfunction in 
anterior optic nerve ischemia, suggesting the important role of OLs in maintaining the 
CNS environment as well as stroke prevention (Dratviman-Storobinsky, et al., 2008; 
Goldenberg-Cohen, et al., 2005). 
2.3.3 Neurological disorders 
Demyelination is also implicated in AD and schizophrenia (see below). In human 
brain, myelination continues for the first fifty or sixty years of life (Berlet, et al., 1980). 
However, OLs are very vulnerable due to their high metabolic activity (Arnett, et al., 
2004). Demyelination in the white matter is correlated with disruption of neural impulse 
transmission, which impairs high cognitive functions such as memory (Bartzokis, 2004). 
Thus, death or dysfunction of OLs is considered to be involved in the pathological 
processes of neurological disorders such as AD and schizophrenia (Bartzokis, et al., 2001; 
Seqal, et al., 2007).  
2.3.3.1 Alzheimer’s disease 
AD is a distinctive human disease that typically presents in older adults. In humans, 
the pathologic lesions of AD may appear as early as the fourth decade of life, during 
which neuronal loss is not typically observed (Breteler, et al., 1992). To mimic AD, 
varieties of non-human models have been established, in both genetic and non-genetic 
forms (Bartzokis, 2004). However, an animal model that includes all AD features has not 
yet been developed. Recent research indicates multiple genetic and environmental risk 
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factors may contribute to AD pathology (Lopez, 2001; Schultz, et al., 2000). In particular, 
detection of increased amyloid β-peptide (Aβ) deposition provides early evidence of AD 
pathogenesis (Selkoe, 1999; Thal, et al., 2002). However, other studies indicate AD 
symptoms may not appear until later years in the life even with accelerating Aβ 
accumulation (Vlkolinsky, et al., 2001).  
Brain size does not independently contribute to AD, as other animals with large 
brains, such as elephants and dolphins, do not develop AD during their life spans. In 
addition, the size of particular brain regions, such as the temporal and frontal lobes, is not 
a risk factor as other higher primates do not develop AD (Semendeferi, et al., 2002). 
Generally, age seems to be the only risk factor for developing AD; however, white matter 
has also recently been identified as a risk factor due to its greater volume in human brains 
in comparison to other animals including higher primates (Semendeferi, et al., 2002). 
OLs in the CNS follow a normal age-related schedule to myelinate axons until the fifth 
decade of life (Bartzokis, et al., 2001). The late-myelinated regions are especially 
susceptible to development of AD, due to the ease of formation of amyloid-rich 
extracellular neuritic plaques (NP) and tau-rich intraneuronal neuronfibrillary tangles 
(NFT), which accelerate AD development in these regions (Thal, et al., 2002; Braak, et 
al., 2000). 
Recent considerable evidence suggests myelin degeneration contributes to AD 
development. First, after myelin degeneration the transport of cholesterol decreases, 
which results in accumulations in particular regions (O’Brien and Sampson, 1965). The 
abundant cholesterol may promote the aggregation of hydrophobic ends of Aβ due to its 
low capacity to bind water. Second, OLs have the highest iron content in the CNS. The 
increased iron levels are required for OLs to myelinate more axons in the aged CNS. Iron 
is also critical to maintain normal protein function and enzyme activity. Recent studies 
indicate increased iron promotes the oligomerization of Aβ, which further facilitates AD 
development (Morath, et al., 2001; Power, et al., 2002). In addition, research 
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demonstrates Aβ preferentially accumulates in unmyelinated or late-myelinating regions, 
which are involved in short-term memory formation (Tallon-Baudry, et al., 2001). These 
studies reveal a strong relation between myelin and AD. Thus, dysfunctional OLs and 
abnormal myelin are implicated in the development of AD but the precise mechanism has 
not yet been resolved. 
2.3.3.2 Schizophrenia 
Schizophrenia is a serious mental disorder that can affect the normal life of a patient. 
Schizophrenia patients can suffer from hallucinations, delusions, and disordered thinking 
as positive symptoms, as well as avolition, anhedonia and apathy as negative symptoms 
(Seqal, et al., 2007). In addition, the patient’s memory, motivation, and language skills 
can also be disturbed (Seqal, et al., 2007).  
A recent study reveals abnormal white matter in the brain plays a key role in 
schizophrenia. The dysfunction of white matter is proposed to result in cognitive deficits 
and impaired memory (Biegon and Eberling 1994). Research indicates white matter is 
somehow disorganized in schizophrenia. Interestingly, the Sox10 gene is highly 
methylated in the brains of schizophrenia patients (Maeno, et al., 2007; Iwamoto, et al., 
2006). Thus, epigenetic modification of OLs may result in white matter dysfunction. As 
Sox10 promotes OL maturation, the decreased expression of Sox10 may lead to 
repression of other OL genes. Indeed, myelin-related genes such as MAG and CNP are 
detected at decreased expression levels in schizophrenia (Voineskos, et al., 2008; Mitkus, 
et al., 2007). Moreover, electron microscopy studies further confirm the OL pathology 
hypothesis of this disorder. For example, apoptotic OLs and abnormal myelin sheaths 
have been detected in schizophrenia brains (Bernstein, et al., 2009). In addition, the 
absolute number of OLs is significantly decreased, which also supports the OL pathology 
hypothesis for schizophrenia (Bernstein, et al., 2009; Butts, et al., 2008).  
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2.3.4 Animal models for the study of demyelination and remyelination  
An important approach to study the mechanisms underlying remyelination after 
degeneration of myelin sheaths is the use of animal models. Several animal models have 
been developed to study the morphological, cellular, and molecular mechanisms that 
regulate remyelination after demyelination in young animal CNS. Each model is designed 
to mimic the pathologies of demyelination disorders such as MS, the most common 
demyelination disease in humans. However, none of these animal models exactly define 
all characteristics of MS.  
At present, the most common animal models include: 1) toxin-induced 
demyelination models, such as the cuprizone model that provides a systemic and chronic 
demyelination (Arnett, et al., 2004; Matsushima, et al., 2001; Doucette, et al., 2010), and 
lysolecithin or ethidium bromide (EtBr) (Skihar, et al., 2009; Yajima and Suzuki, 1979) 
that produce rapid demyelination; 2) autoimmune-induced demyelination models, such as 
EAE (Traugott, et al., 1985; Yang, et al., 2010); and 3) viral-induced demyelination 
models (Carlson, et al., 2010; Lang, et al.,1984).  
Virus models are also widely used to investigate demyelination and remyelination 
because viruses can induce inflammatory demyelination disease in the CNS. To study 
demyelination, viruses are injected to induce infection. The most commonly used viruses 
are Theiler’s murine encephalomyelitis virus (TMEV), Semliki forest virus (SFV), and 
mouse hepatitis virus (MHV). Briefly, TMEV is natural pathogen of mice. Demyelination 
is observed in the TMEV model with the destruction of OLs (Carlson, et al., 2010; 
Rodriguez, et al., 1983). In the MHV model, auto-reactive T cells are generated due to 
inflammation (Baumann and Pham-Dinh, 2001). Compared to other virus-mediated 
models, SFV is easier to administer due to its ability to penetrate the blood-brain-barrier 
(Mokhtarian, et al., 1999). 
The EAE model is widely used in the study of MS, as it produces both inflammation 
and demyelination. It can be induced by either myelin protein-mediated immune reaction 
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or T cell-mediated inflammation in the CNS (Bradl and Linington, 1996). However, the 
period between sensitization and onset of MS depends upon both genetic and non-genetic 
factors. Recently, more and more myelin proteins have been identified and used as 
antigens to induce MS pathology in the EAE model, these include MBP, PLP, MAG, and 
MOG (Bradl and Linington, 1996). However, MOG is the only one at present that can 
induce both the T cell-mediated response and the myelin protein mediated reaction in 
EAE model (Baumann and Pham-Dinh, 2001). Interestingly, MOG is critical for the 
induction of demyelination as only inflammation has been found in MBP-induced EAE 
(Baumann and Pham-Dinh, 2001). However, massive demyelination is present after 
intravenous injection of the anti-MOG antibody (Linington, et al., 1988). 
Compared to inflammation models, toxin-induced animal models provide the 
opportunity to independently test demyelination. In particular, EtBr and lysolecithin are 
commonly used to produce rapid onset demyelination (Franklin, et al., 2002; Franklin, 
2008; Hinks and Franklin, 2000). Research based on using chemical injection verifies the 
rapid recruitment of OPCs as well as the steps in OL maturation (Franklin, et al., 2002; 
Franklin, 2008; Hinks and Franklin, 2000).  
Another toxin-induced model, the cuprizone model, has been widely used to 
investigate remyelination responding to chronic demyelination. In this model, young 
adult mice fed with cuprizone, a copper chelator (Matsushima and Morell, 2001; 
Doucette et al., 2010), show massive degeneration of myelin sheaths in the CNS white 
matter, particularly in rostral corpus callosum (RCC) and superior cerebellar peduncle 
(SCP) (Komoly, et al., 1984; Stidworthy, et al., 2003; Doucette et al., 2010). In addition, 
spontaneous remyelination is observed as early as 4 days after cuprizone withdrawal, 
verifying the important role cuprizone plays in this model. Indeed, to sustain the high 
expenditures due to their large volume of cytoplasm, OLs require more energy compared 
to other cell types. Thus, OLs are extremely susceptible to cuprizone, as copper is critical 
for proper mitochondrial function (Torkildsen, et al., 2008). Moreover, the C57BL/6 
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mice strain is commonly used due to its genetic and phenotypic uniformity (Torkildsen, 
et al., 2008). Recent research suggests the dose of cuprizone in regular chow should be 
around 0.2% to 0.3% by weight, as only OLs but not other cell types such as astrocytes in 
the CNS are affected at this dosage (Torkildsen, et al., 2008). Additionally, both MS and 
EAE involve complex immune response and T cell activation. However, T cells are 
almost absent in cuprizone-induced demyelination model. Recent studies indicate that for 
some MS patients, death of OLs is the earliest change in some lesions, which challenge 
the previous autoimmune theory. Thus, cuprizone model provide supplemental 
information to studies of demyelination and remyelination processes.  
The animal models discussed above make possible the investigation of the stepwise 
development of OPCs as well as the mechanisms of demyelination and remyelination. 
However, novel technologies and animal models need to be developed to further 
elucidate the mechanism of age-related remyelination. Gene expression profile assays and 
a further understanding of protein structures will contribute to better definition of these 
processes.  
 
2.4 Aging and CNS remyelination  
Recent research demonstrates OPC recruitment occurs rapidly in response to 
demyelination lesions in the young adult CNS, followed by morphological changes of 
OPCs into OLs. Ultimately, mature OLs wrap the axons and form novel myelin sheaths. 
However, efficient recovery is difficult to sustain in aging animals (Shen, et al., 2008).  
In general, the ability of OLs to myelinate axons is essential to the proper repair 
after injury. However, similar to other processes, remyelination efficiency of OLs 
declines with age (Shen, et al., 2008; Ando, et al. 2003; Berlet, et al., 1980). Abundant 
research over the several years has attempted to explain this phenomenon. Both the 
decreased rate of OPC recruitment and problems during the differentiation of OPCs have 
contributed to evolving theories, but alterations of TF expression are likely the reason for 
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impaired OPC recruitment and differentiation (Franklin, et al., 2002; Sim, et al., 2002). 
In addition, the differences in OL lineage cells in old vs. young animals are associated 
with the age-related expression levels of growth factors, which are essential for 
proliferation, migration, and differentiation of OPCs (Franklin, et al., 2002). Furthermore, 
a higher metabolic rate is required for OLs to myelinate an increasing number of axons as 
well as demyelinating regions. Thus, repair of injured myelin sheaths is especially 
difficult. Moreover, epigenetic control seems to be involved in many aging related 
processes (Shen, et al., 2008).  
Transgenic techniques are widely used in experiments attempting to explain possible 
reasons for the age-related decline in myelination efficiency. By over-expressing, 
truncating, or deleting genes required for OPC recruitment and OL maturation in adult 
animals, more details are now beginning to be understood (Franklin, et al., 2002; Hinks, 
et al., 2000). Many studies indicate a temporal delay in growth factors in old animals 
compared to young. These delayed growth factors, such as PDGF and FGF, are critical to 
oligodendrogenesis and therefore may contribute to the recruitment and maturation of 
OLs (Franklin, et al., 2002; Hinks, et al., 2000).  
For many years, it could not be determined whether OPC recruitment or OL 
maturation determined the slow remyelination rate in aged animals. However, research 
now shows both are essential. On one hand, there is an age-related decline in OPC 
recruitment. Studies indicate different numbers of PDGFαR+ cells in the caudal 
cerebellar peduncles of young and old animals, suggesting the recruitment of OPCs may 
decrease remyelination (Zhao, et al., 2005). In addition, the rate of OPC recruitment 
decreases with age, as PDGFαR mRNA levels are significantly lower in older animals 
(Franklin, et al., 2002). On the other hand, an age-related impairment in OL 
differentiation has been described, indicating the remyelination process may be halted at 
this step (Blakemore and Keirstead, 1999). Research indicates a delay in MBP and PLP 
mRNA expression in old mice after EtBr injection (Franklin, et al., 2002), suggesting OL 
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differentiation is blocked. Moreover, an age-dependent epigenetic inhibition has been 
described. Research indicates that histone deacetylases (HDACs) are not present in 
sufficient quantities in aging animals, and thus transcriptional inhibitors accumulate and 
prevent the subsequent myelin gene expression (Shen, et al., 2008). Macrophages may 
also contribute to effects of aging on remyelination. A notable difference in cellular 
environments has been reported (Zhao, et al., 2008). Macrophages can remove myelin 
debris, which is harmful to remyelination after demyelination (Sun, et al., 2010; 
Henderson, et al., 2009). Thus a delayed reaction by macrophages in some cases can 
delay remyelination. Nevertheless, the precise mechanisms still need to be resolved and 
are dependent on the complicated signaling pathways in the CNS. 
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III Materials and methods 
The following methods and protocols were used to accomplish the objectives 
identified in Section 1.2.  
3.1 Cuprizone 
The neurotoxicant cuprizone is a copper chelator that reproducibly induces massive 
demyelination in large areas of the mouse brain (McMahon, et al., 2001). OLs are 
especially vulnerable to this neurotoxicant because of their high metabolic activity, which 
is dependent on copper for proper mitochondrial function. The administration of 
cuprizone causes cell death of OLs, which leads to extensive demyelination of select 
myelinated fiber tracts in adult mice (Armstrong, et al. 2002). The two best studied fiber 
tracts are the corpus callosum (Morell, et al., 1998; McMahon, et al., 2002) and the 
superior cerebellum peduncle (Komoly, et al., 1992). Review by Torkildsen (Torkildsen 
et al., 2008) discussed the cuprizone model in detail. In the standard model, young adult 
mice are fed with 0.2%-0.3% cuprizone in the chow. Under this dosage, OLs seem to be 
the only glial cell type o be affected in the CNS. 
Although cuprizone is a copper chelator; the administration of copper is not an 
antidote (Carlton et al., 1967). The assumed mechanism of cuprizone to kill OLs is that 
the cuprizone leads to inhibition of the copper-dependent mitochondrial enzymes 
cytochrome oxidase and monoamine oxidase (Matsushima and Morell, 2001).  
3.2 Animal Protocols 
Cuprizone is ideal for studying remyelination because cuprizone-induced 
demyelination is easily inducible, localized, and predictable. In addition, cuprizone model 
only associates with microglia/macrophages response but not T cell activation, which 
mimic early MS symptoms (Baumann and Pham-Dinh, 2001). In this project, we 
developed the classic model using cuprizone to induce demyelination in mice. Instead of 
using only young animals, the extension of age was designed as a factor to alert the 
response of OLs to demyelination lesions.  
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With the experimental design (Figure 7), there were three groups: a) control mice, b) 
cuprizone-treated mice, and c) cuprizone recovery mice. Young adult (2-month old), 
adult (6-month old), and aged (12, 16-month old) C57BL/6 mice were fed with 
cuprizone-treated (0.2% by weight, mixed with their diet of milled chow) or control food 
for a period of 6 weeks. At the end of the 6th week, half of the animals (n=9) were 
sacrificed, and the remainder (n=9) fed normal food for an additional 3 weeks (for myelin 
recovery). Animals were euthanized by perfusion (for immunohistochemistry, n=3) or 
dissected brains were fresh frozen (for Quantitative Real Time PCR, n=3) (Figure 7).  
3.3 Perfusion 
Three animals from each group were perfused for further immunohistochemical 
study. The mice were perfused through the heart under deep anesthesia. The mice were 
first perfused with phosphate buffered saline (PBS), and then pefused with cold freshly 
made 4% paraformaldehyde (pH 7.4). After perfusion, brain tissues were quickly 
removed and post-fixed in 4% paraformaldehyde overnight (Doucette et al., 2010). The 
next day the tissues were transferred into 30% sucrose for storage.  
3.4 Immunohistochemistry 
Whole half brains were embedded in optimal cutting temperature (OCT) compound 
(Tissue-Tek), and serially sectioned (8 µm) in either coronal or sagittal planes with a 
cryostat onto gelatin coated coverslips (Figure 8). The sections were air dried at room 
temperature for 30 min?and kept at -20°C for further use. For immunohistochemical 
study, the sections were rehydrated in PBS for 2 x 10 min. The sections were then 
blocked in 3% SM-PBST (3% skim milk and 1% Triton X-100 in PBS) for 40 min. 
Sections were then exposed to the diluted primary antibody in PBS at 4°C overnight. 
Primary antibodies were diluted in PBS. The sections from each animal were exposed to 
MOG and MBP as single staining, PDGFαR/Olig2, PDGFαR/GFAP, Olig2/GFAP as 
double labeling. Table 1 lists the titers of the antibodies employed. The unhybridized 
primary antibody was then rinsed off twice with PBS. The secondary antibody was then 
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applied for 45 min. at room temperature. Distinctive secondary antibodies were employed 
to hybridize primary antibodies (see Table 1). After two washes in PBS, the sections were 
counterstained with Hoechst dye (Sigma) to visualize the nuclei. Finally, the sections 
were rinsed twice in PBS, mounted in Prolong (Molecular Probes), and visualized with 
fluorescence microscopy.  
3.5 Microscopy 
At least 20 consecutive tissue sections were collected at intervals of 300 µm, where 
CC begins to cross rostrally at the anterior commissure. Olympus CKX41 light 
microscopy was used to image the immunohistochemical stained tissue sections with 
objective lens magnification of either X10 or X20. Images were taken with a Nikon 
CoolPix4500 digital camera. Fluorescent images were observed with an Olympus BX40 
filter system with appropriate filter sets. Under fluorescence microscopy, the rostral 
corpus callosum (RCC) of each section was captured by digital camera. For MOG 
staining, images were taken with X10 objective lens. For double staining, three adjacent 
images within the medial aspects of the RCC (500 µm2) were captured from the midline 
of the brain, each section were imaged using X20 objective lens. All images were saved 
on the computer hard drive and further analyzed with Image-Pro Express® software 
(Media Cybernetics). 
3.6 Blinded Cell Counts 
After immunofluorescent staining, each section was assigned a code and all cells 
were counted blindly. Sections of PDGFαR/Olig2 and GFAP/Olig2 double labeling were 
analyzed by testing cell population. Cells were counted manually using Image-Pro 
Express® software. The numbers of double stained cells in each image were counted in 
terms of as nuclear expression (eg. Olig2Nuc+ve), cytoplasmic expression (eg. 
Olig2Cyto+ve), and any co-expression. The data collected from the sections were total cell 
density, co-expression of Olig2Nuc+ve/PDGFαR+ve, Olig2Nuc+ve/GFAP-ve, 
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PDGFαR+ve/GFAP-ve, Olig2Cyto+ve/GFAP+ve, Olig2Cyto+ve/ PDGFαR+ve, and 
Olig2Cyto-ve/GFAP+ve. Total cell density was visualized by Hoechst stained nuclei.  
3.7 mRNA Isolation and Reverse Transcription (RT) 
Specific areas of each mouse brain, including the anterior corpus callosum, posterior 
corpus callosum, anterior hippocampus, posterior hippocampus, and cortex were selected 
from frozen fresh brains. However, only the anterior CC was used for further studies. 
Total mRNA was isolated using a RNeasy Protect Mini Kit (Qiagen) according to the 
manufacturer’s protocol. RNA concentration was determined by UV spectrophotometry 
(Ultrospec 3100 pro). First strand DNA synthesis (RT) was performed with the 
SuperScript® first strand synthesis kit (Invitrogen) with random primers using the 
manufacturer’s protocol. The final concentration of total RNA for RT was 20 ng/µL. 
3.8 Quantitative RT PCR 
Specific factors such as MOG, Olig2, CGT, Nkx2.2, PDGFαR, and β-actin (as 
internal standard) were detected by quantitative RT-PCR (7300 Biosystems) using 
commercially available primers (Applied Biosystems). All reactions are performed using 
the Taqman Universal Master Mix, FAM-labeled Taqman Gene Expression assays for 
genes of interest, VIC-labeled Taqman Endogenous Control β-actins, and 10 ng of cDNA 
as a template. All reactions were run in replicates of 4, and n=3 animals were used for 
each gene per group. Thermocycling parameters were as follows: 2 min at 50°C, 10 min 
at 95°C, 40 cycles of 15 s at 95°C, and 70 s at 60°C. All comparisons are conducted with 
relative quantification software (Applied Biosystems). Related Quantitative (RQ) values 
were obtained by quantitative RT PCR, and normalized to the mean value of the 
respective 2 month control mice. Normalized RQ values greater than 1 indicate increased 
gene expression, while RQ values less than 1 indicate decreased gene expression levels 
compared to the 2 month control.  
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3.9 Statistical analysis  
For immunohistochemistry experiments, cell density was calculated for the data 
from each treatment group. Data was further analyzed by two-way ANOVA followed by 
Bonferroni’s post-hoc multiple test (GraphPad Prism). Data for MOG, CGT, PDGFαR, 
Olig2, and internal control (β-actin) from quantitative real time PCR were analyzed by 
two-way ANOVA followed by Bonferroni’s post-hoc multiple test (GraphPad Prism). A 
p value less than 0.05 was considered to be significant. 
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Schematic diagram illustrating experimental design of this study 
 
Figure 7. A diagram illustrating experimental design of the study. There were three 
treatment groups: a) control mice, which were fed normal milled chow for 6 weeks; b) 
cuprizone mice, which were fed a 0.2% cuprizone-containing diet for 6 weeks; and c) 
cuprizone recovery mice, which were fed 0.2% cuprizone diet for the first 6 weeks 
followed by normal milled chow for the next three weeks.  Six mice were used for each 
of the three treatments at each of the four ages.  Half of the mice for each treatment and 
age were used for immunofluorescent microscopy and the remaining half for collecting 
tissue for quantitative RT-PCR (qRT-PCR). 
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Table 1. Titers of the antibodies used in immunohistochemistry 
 
Primary antibody Secondary antibody 
Antibody Titer? Antibody Titer 
PDGF ? R  
(BD Pharmingen)?
1:100? Alexa Fluor 594 goat anti rat IgG? 1:400?
GFAP??
(Dimensionlabs)? 1:1000?
Alexa Fluor 488 
goat anti rabbit IgG? 1:200?
GFAP  
(Sigma)? 1:1000?
Alexa Fluor 488 
goat anti mice IgG? 1:200?
Olig2?
(Takebayashi)? 1:1000?
Alexa Fluor 594 
goat anti rabbit IgG? 1:400?
MBP 
(Sternberger)? 1:1000?
Alexa Fluor 594 
goat anti mice IgG? 1:400?
MOG 
(Gardinier)? 1:3 
Alexa Fluor 594 
goat anti mice IgG? 1:400?
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  Schematic diagram to show tissue section and collection 
 
Figure 8. A diagram summarizing how the brain was dissected for cutting sagittal and 
coronal cryostat sections.  ‘A’ The brain is removed from the skull and separated down 
the midline (‘B’), thus dividing the brain into a right and a left half.  ‘C’ shows a 
midsagittal section of the right cerebral hemisphere, including the genu (arrow) and body 
of the corpus callosum.  Myelin protein immunostaining was done on cryostat sagittal 
tissue sections to see age-related differences in cuprizone-induced demyelination in the 
corpus callosum and the extent of myelin repair in the cuprizone recovery mice.  The 
long, thin rectangle passes through the rostral part of the body of the corpus callosum and 
indicates the plane of section for the drawing in ‘D’, which shows the coronal plane 
through the brain. This coronal plane was used for all of the immunostaining for 
quantifying cell densities, with the quantification done on digital images captured from 
the medial part of the corpus callosum, which is indicated by the boxed area in ‘D’.  
Three adjacent images were taken from the midline of the brain, medially to laterally. 
The corpus callosum tissue used for qRT-PCR was obtained from a comparable area 
within the medial aspect of this myelinated fiber tract.  
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IV Results 
4.1 Health condition of mice fed the control or cuprizone diet 
Each mouse was weighed daily until they were killed for the study. The daily 
weighing enabled us to trace the effect of the cuprizone diet on their eating habits as well 
as the normal weight with aging. We also observed the behavior of the mice, and found 
nothing unusual in both control and cuprizone fed mice. With the exception of body 
weight loss, and a few dermatitis problems, all the mice were considered healthy until 
they were killed for immunostaining or quantitative RT PCR.  
4.2 Effectiveness of cuprizone-induced demyelination of RCC 
To test the effectiveness of cuprizone contained diet on mice aged 2-16 months old, 
coronal and sagittal sections from control and cuprizone-fed mice were immunostained 
with MBP and MOG antibodies. Under fluorescent microscopy, both MBP and MOG 
staining showed a similar expression pattern of demyelination in the RCC of mice of all 
ages (Figure 9, 10 and 11). MBP and MOG positive expression indicate myelin sheaths, 
which represent mature OLs.  
Mice were fed a cuprizone-containing diet for 6 weeks to develop demyelination. 
Spontaneous remyelination was expected after the withdrawal of cuprizone diet after 3 
weeks. As expected, massive demyelination was observed in the RCC of mice after 6 
weeks of cuprizone fed. The immunostaining indicate a similar loss of MBP and MOG in 
the cuprizone fed mice of all 4 ages. As well, no age-related difference was observed in 
the control mice across all ages. However, noticeably less immunostaining of MBP and 
MOG was found in the RCC of 12 and 16 month-old cuprizone recovery mice compared 
to the 2 and 6 month-old cuprizone recovery mice. The immunostaining of MBP and 
MOG suggests that there may be age-related differences in OPCs recruitment or OL 
maturation, as well as altered myelin gene expression (Figure 9, 10, and 11). 
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  Immunohistochemical analysis of MBP in the RCC of 2, 6, 12, and 16 month-old mice 
 
 
 
 
Figure 9. Immunohistochemical analysis of MBP in RCC of 2, 6, 12, and 16 month-
old mice: untreated control (A, D, G and J), 6 week cuprizone treated (B, E H and K), 
and 6 week cuprizone treatment followed by 3 week recovery (C, F, I and L). An age-
related decline in MBP expression is evident (A, D, G and J). Cuprizone fed mice show 
decreased expression of MBP in the RCC (B, E, H, K compared to A, D, G, J) that 
recovers in 2 and 6 month old mice (C, F compared to A, D) after a period of 3 weeks 
but does not recover as well in 12 and 16 month old mice (I, L compared to G, J). n=3, 
bar=50 microns. 
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Immunohistochemical analysis of MOG in coronal sections through 
the CC of 2, 6, 12 and 16 month-old mice 
 
 
 
 
Figure 10. Immunohistochemical analysis of MOG in coronal (A-L) sections 
through the CC of 2, 6, 12 and 16 month-old mice: control (A, D, G, and J), cuprizone 
(B, E, H, and K), cuprizone recovery (C, F, I, and L). Cuprizone fed mice show 
decreased expression of MOG in the RCC (B, E, H, K compared to A, D, G, J) that 
recovers in 2 and 6 month old mice (C, F compared to A, D) after a period of 3 weeks 
but does not recover as well in 12 and 16 month old mice (I, L compared to G, J). n=3, 
bar in ‘A’ = 100 microns (applies to ‘A’ to ‘L’ ). 
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Immunohistochemical analysis of MOG in sagittal sections through 
the CC of 12 and 16 month-old mice 
 
Figure 11. Immunohistochemical analysis of MOG in sagittal (M-X) sections 
through the CC of 12 and 16 month-old mice: control (M, P, S and V), cuprizone (N, Q, 
T and W), cuprizone recovery (O, R, U and X) mice.  The boxes in ‘M’ to ‘R’ indicate 
the areas in the RCC shown in higher magnification in ‘S’ to ‘X’, respectively. 
Cuprizone fed mice show decreased expression of MOG in the RCC of mice (T,W 
compared to S, V) that does not recover after 3 weeks in 12 and 16 months old mice (U, 
X compared to S, V). n=3, bar in ‘M’ = 200 microns (applies to ‘M’ to ‘R’), bar in ‘S’ = 
100 microns (applies to ‘S’ to ‘X’). 
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4.3 Changes in myelin gene expression during normal aging 
To determine if there were age-related changes in myelin gene expression, 
quantitative RT PCR was employed to quantify the expression levels of myelin genes in 
the RCC of mice. The expression of two genes quantified were MOG and CGT. MOG 
expression represents the late stage of OLs that myelinate axons, CGT represents the 
early stage of OL during development, respectively. The RQ values for each gene were 
normalized to the mean RQ value of the 2 month control mice. The statistical significant 
differences were assessed using a two-factor ANOVA (Figure 12).  
The expression levels of MOG in control mice underwent an age-related decrease 
(Figure 12A). The normalized RQ values for MOG at 16 months old were 4-fold lower 
than 2 months old control mice. As well, there was an age-related decrease of CGT gene 
expression (Figure 12B). However, there was less than a 2-fold decrease of CGT 
expression in contrast to the 4-fold reduction of MOG expression in the RCC of these 
same mice.  
4.4 Expression of myelin genes in response to cuprizone-induced demyelination 
We predicted that myelin gene expressions in the RCC of mice would be decreased 
in response to cuprizone treatment. However, the expected reduction of MOG gene 
expression was seen only at 2 month-old group (p<0.5) (Figure 12A). In contrast to 
normal aging, there were no significant differences of MOG expression in response to 
cuprizone-induced demyelination at 6, 12, and 16 months mice. In addition, there were no 
significant differences of MOG expression between 4 ages. Thus, the MOG expression in 
response to cuprizone-induced demyelination was similar at all four ages (Figure 12A).  
The RQ values revealed that cuprizone treatment differentially affected CGT gene 
expression in the RCC of mice. The only statistical difference as indicated by 
Bonferroni’s post test was a significant increase of CGT expression at 12 month-old, 
compared to the age-matched control (p<0.5)(Figure 12B). However, this function is not 
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common in older mice since the CGT expression level of 16 month-old group was not 
significant from that of age-matched control mice (p>0.5) (Figure 12B). 
4.5 Changes in myelin gene expression after three weeks recovery 
The gene expression levels of MOG and CGT after 3 weeks recovery indicate the 
ability of OLs to repair damaged tissues. Thus any increase of myelin gene expression 
was an attempt by OLs to recover from cuprizone-induced demyelination in the recovery 
period. The statistical analysis revealed that the normalized RQ value of MOG after 
recovery was significantly higher at 2, 12, and 16 month-old mice compared to the age-
matched cuprizone mice (p<0.5) (Figure 12A). The increase of MOG gene expression 
was between 1.8 fold (16 months old) and 2.5 fold (12 months old). In addition, the 
normalized RQ value of MOG was significantly increased compared to age-matched 
control mice at 12 and 16 month-old mice (p<0.5) (Figure 12A). Therefore, there were 
significant increases of MOG expression after 3 weeks of cuprizone withdrawal, even in 
the older age of the mice.  
With respect to CGT expression of cuprizone recovery mice, there was no 
significant difference among most of the RQ values normalized to 2 months control. The 
only difference was observed at 12 month-old of age. The expression of CGT was 
increased compared to the age-matched control (p<0.5) (Figure 12B). In addition, 16 
months of age group showed a similar trend but did not reach significance (p>0.5). Thus, 
unlike the MOG recovery pattern, aging has less effect on CGT expression after 3 weeks 
of cuprizone recovery mice. The expression of CGT gene in response to withdrawal from 
cuprizone-contain diet was similar at all four ages.  
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Histograms depicting gene expression profiles for MOG and 
CGT in the RCC 
 
 
  Figure 12. Histograms depicting the gene expression profiles (quantitative [q] RT-PCR) 
for MOG (A), and CGT (B) in the RCC of 2-16 month-old control, cuprizone and 
cuprizone recovery mice (n=3). The qRT-PCR data are expressed as normalized RQ 
values, with all RQ values for a gene being normalized to the mean RQ value of the 
respective 2 month-old control mice. For MOG expression (A), the two-way ANOVA 
showed significant main effects of age (p<0.0001) and treatment (p<0.0001), as well as 
a significant interaction effect (p<0.0001).  For CGT expression (B), the two-way 
ANOVA showed a significant main effect of age (p=0.04) and a significant interaction 
between age and treatment (p<0.0001); the main effect of treatment was nonsignificant 
(p>0.05). For all histograms, the brackets in color denote significant age-related 
differences within a group, whereas black brackets denote significant treatment-related 
differences (Bonferroni’s post-test; significance level of p<0.05). 
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4.6 Changes in OL specific gene expression during normal aging 
The expression of OL specific genes such as PDGFαR, Olig2, and Nkx2.2 are 
critical to OL development and myelination. In the subsequent experiments, we asked 
whether there were age-related changes in expression of these genes. The RQ values of 
PDGFαR, Olig2, and Nkx2.2 genes were normalized to that of 2 months old control mice 
respectively. We employed two-way ANOVA as statistical analysis, in which age and 
treatment worked as the factors.  
We did not find any significant difference in the expression of PDGFαR gene in the 
2-16 months control mice (p>0.5) (Figure 13A). However, a significant age-related 
reduction of Olig2 gene expression was observed in the RCC of control mice (p<0.5) 
(Figure 13B). The normalized RQ value at 16 months old was about 3.3 fold lower than 
that of 2 months control. Compared to the decreased expression of Olig2 gene, the 
normalized RQ values of Nkx2.2 revealed a significant increase in older age of mice. For 
instance, the RQ value of Nkx2.2 at 16 months control mice (2.78 +/-0.47) was 2.6-fold 
higher than that of 2 months old mice (1.06 +/-0.11) (p<0.5). Therefore, age affected 
expression of Olig2 and Nkx2.2 differentially.  
4.7 Changes in OL specific gene expression during cuprizone treatment 
Unexpectedly, PDGFαR gene expression was only affected in 2 month-old mice 
RCC during cuprizone-induced demyelination. There was a significant reduction in RQ 
value at 2 months cuprizone mice (0.58 +/-0.05) compared to the age-matched control 
mice (1.0 +/-0.1) (p<0.5) (Figure 13A). However, we did find an age-related increase in 
PDGFαR expression in the RCC of cuprizone mice. The expression level in 12 month-old 
was significantly higher than that in 2 and 6 months old cuprizone mice (p<0.5) (Figure 
13A).  
For Olig2 gene, the expression was significantly higher in 12 and 16 month-old 
cuprizone mice compared to the age-matched control (p<0.5) (Figure 13B). However, the 
normalized RQ value of Olig2 in 2 months cuprizone mice was significantly lower than 
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the age-matched control. For Bonferroni’s post test, the RQ value in 12 month-old mice 
was significantly higher than that of 2 months cuprizone mice (p<0.5) (Figure 13B).  
With respect to the expression of Nkx2.2, it failed to reach statistical significance 
between cuprizone mice and age-matched control mice in all four age groups (Figure 
13C). Thus we assume that age is the main factor in impacting gene expression of Nkx2.2 
gene. Similar to the control aged mice, the expression of Nkx2.2 was significantly 
increased in the older mice compared to the younger aged mice following cuprizone 
treatment. The RQ values revealed that there were more than 2 fold increases at 12 
(2.53+/-0.45) and 16 (2.24 +/-0.44) months cuprizone mice than that of 2 months 
cuprizone mice (0.95 +/-0.08) (p<0.5) (Figure 13C).  
4.8 Changes in OL specific gene expression after cuprizone recovery 
For PDGFαR gene expression, there were no significant changes between cuprizone 
and cuprizone recovery mice in all four ages (p>0.5) (Figure 13A). However, 
Bonferroni’s post test revealed that gene expression level in 12 months old cuprizone 
recovery mice was significantly higher than that of 2 and 6 month-old cuprizone recovery 
mice. In addition, the RQ value of PDGFαR in 16 months cuprizone recovery mice was 
significantly higher than that in 6 months cuprizone recovery mice (p<0.5) (Figure 13A). 
Moreover, there was significantly increased PDGFαR gene expression in the RCC of 12 
months cuprizone recovery compared to the age-matched control mice (p<0.5) (Figure 
13A).  
With respect to Olig2 gene, expression levels were significantly decreased in the 
recovery mice at 6 and 16 month-old compared to the age-matched cuprizone mice 
(p<0.5) (Figure 13B). Furthermore, a significant decrease in Olig2 expression in the RCC 
of 2 month-old cuprizone recovery mice was revealed compared to the age-matched 
control mice. However, a significant increase of Olig2 in 12 month-old recovery mice 
was observed compared to the age-matched control (p<0.5) (Figure 13B).  
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None of the significant differences in Nkx2.2 gene expression was detected between 
cuprizone and recovery mice at all four ages (p>0.5) (Figure 13C). However, an age-
related increase of Nkx2.2 gene expression in the RCC of cuprizone recovery mice was 
observed by Bonferroni’s post test. The normalized RQ values of 12 months cuprizone 
recovery mice were significantly higher than that of 2 and 6 months recovery mice (p<0.5) 
(Figure 13C). In addition, the expression level of Nkx2.2 at 16 months was up to 5-fold 
higher compared to 2 and 6 months cuprizone recovery mice (p<0.5) (Figure 13C).  
4.9 Cell densities of Hoechst +ve nuclei (total cell numbers) 
The Hoechst+ve nuclei indentified the total cell number. We counted the cell 
number in each of three images that were captured from the main area of RCC (Figure 8). 
Two-factor ANOVA was employed to analyze the aspect of aging and cuprizone 
treatment. It was shown that there was no age-related difference in total cell density in the 
RCC of control mice in all four ages (p>0.5) (Figure 14A). Due to this result, we 
confirmed that the main effects of aging on myelin genes were not due to any changes in 
total cell densities (Figure 14A).  
In contrast to control mice, the only statistical difference in total cell densities 
between cuprizone and control mice was shown at 2 months of age. There was a 
significant increase in cell number after treatment of cuprizone (p<0.5) (Figure 14A). In 
addition, the total cell densities at 6, 12, and 16 months of cuprizone mice were 
considerably less than that at 2 months of age (p<0.5) (Figure 14A). Therefore, it is 
possible that the response to cuprizone treatment was impaired in the aged mice 
compared to the 2 month-old mice.  
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Histograms depicting gene expression profiles for PDGFαR, 
Olig2, and Nkx2.2 in the RCC 
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Figure 13. Histograms depicting the gene expression profiles for PDGFαR (A), 
Olig2 (B), and Nkx2.2 (C) in the RCC of 2-16 month-old control, cuprizone, and 
cuprizone recovery mice (n=3). The RQ values were normalized to the mean value of 2 
months control mice. A) A significant effect of age (p=0.0001) and interaction between 
age and treatment (p<0.009) on PDGFαR gene expression was revealed. B) For Olig2 
expression, the two-way ANOVA revealed main effects of age (p=0.0001) and 
treatment (p<0.0001), as well as the interaction between age and treatment (p<0.0001). 
C) The two-way ANOVA on the RQ values of Nkx2.2 showed a significant main effect 
of age (p<0.0001) as well as the interaction between age and treatment (p<0.05). The 
brackets denote significant differences (Bonferroni’s post test, p<0.05). 
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After three weeks of cuprizone withdrawal, the only difference in cell density was 
noted in 2 months cuprizone recovery compared to the age-matched control. There was 
approximately 42.6% increase in total cell density (p<0.5) (Figure 14A,B,D). In contrast 
to 2 months of age, the 6, 12, and 16 months cuprizone recovery mice failed to reach the 
statistical significance in comparison to the age-matched control (p>0.5) (Figure 
14A,C,E). Interestingly, similar to cuprizone mice, the tissue response of older mice with 
respect to cell density was considerably lower than that of 2 month-old cuprizone 
recovery mice (Figure 14A,D,E).  
4.10 Changes in density of cells of the OL lineage after cuprizone-induced 
demyelination and three weeks recovery 
In the subsequent experiments, we traced oligodendrogenesis in the RCC. Olig2 
functions as a TF in OL lineage cells. As mentioned previously, it plays important role in 
specification, differentiation and maturation of OLs (Nicolay, et al., 2007). Furthermore, 
the translocation of Olig2 protein determines the cell fate of OPCs. For example, Olig2 
localized in the nucleus will induce OPCs to differentiate into myelinating OLs (Zhao, et 
al., 2009). However, cytoplasmic translocation of Olig2 can lead the OPCs to undergo the 
astrocyte pathway (Cassinani-Ingoni, et al., 2006; Magnus, et al., 2007; Zhao, et al., 
2009). Therefore, we collected cell data separately as Olig2Nuc+ve and Olig2Cyto+ve, 
respectively, with OL or astrocyte lineage cell markers (Figure 15).  
For immunohistochemistry study, we used double labeling of PDGFαR with Olig2, 
PDGFαR with GFAP, and Olig2 with GFAP respectively. The PDGFαR+ve/GFAP-ve 
cell represented glial progenitor (Figure 16C,F); PDGFαR+ve/ Olig2Nuc+ve represented 
OL progenitor (Figure 16B,E); and Olig2Nuc+ve/GFAP-ve cells represented OL lineage 
cells (Figure 16A,D). Instead of comparing the cell densities between ages, the statistical 
analysis focused on the effects of treatment on the cell densities of these three cell 
phenotype at a single age. The two-way ANOVA was employed, where the phenotype of 
the cells and treatment were used as the independent variables.  
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Histogram depicting the mean number of Hoechst +ve nuclei in the RCC 
 
Immunohistochemical staining depicting the Hoechst +ve nuclei in the RCC 
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Figure 14. A) Histogram depicting the mean number of Hoechst +ve nuclei in the 
RCC of 2-16 months old control, cuprizone-treated, and cuprizone recovery mice (n=3). 
Data revealed that the age and treatment were main effects on the cell densities 
(p<0.0001), as well as the interaction between age and treatment (p<0.0001). The 
brackets denote significant differences (Bonferroni’s post test, p<0.05). B,C,D,E) 
Hoechst +ve nuclei in the RCC of 2 months control (B), 16 months control (C), 2 
months cuprizone recovery (D), and 16 months cuprizone recovery mice (E). Bar=50 
microns.  
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For cell densities of glial progenitors (PDGFαR+ve/GFAP-ve), a significant 4.2- to 
3.1-fold increase after cuprizone treatment (16.0 +/- 3.35) and recovery (11.59 +/- 2.04) 
was found in the RCC of 2 months old mice, compared to that of 2 months old control 
mice (3.78 +/- 0.61), respectively (p<0.5) (Figure 17A). However, there were no 
significant differences in glial progenitors at 6, 12, and 16 months cuprizone and 
cuprizone recovery mice (p>0.5) (Figure 17B,C,D). In addition, for OL progenitors 
(PDGFαR+ve/ Olig2Nuc+ve), none of treatment-related differences were observed at any 
of the ages (p>0.05) (Figure 17 A-D).  
With respect to OL lineage cells (Olig2Nuc+ve/GFAP-ve), Bonferroni’s post test 
revealed that the cell densities were higher in control mice RCC compared to cuprizone-
treated and cuprizone recovery mice. For instance, cell number of OL in the 2 month-old 
control mice (20.27+/-3.05) was 8.2- and 2.3-fold higher than that of cuprizone (2.48+/-
0.88) and cuprizone recovery (8.33+/-2.44) mice (p<0.5) (Figure 17A). In the RCC of 6 
months old mice, cell densities of control mice (16.28+/-3.41) was significantly higher 
than that of cuprizone mice (5.98+/-3.14) (p<0.5) (Figure 17B). Similar to the 2 month-
old mice, the cell densities of OL lineage cells were considerably lower after cuprizone 
treatment and cuprizone recovery (Figure 17C). As well, there was a decline of cell 
number after cuprizone recovery at 16 month-old mice, compared to the age-matched 
control (Figure 17D).  
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Translocation of Olig2 protein determines the cell fate of OPCs 
 
 
 
 
 
Figure 15. Translocation of Olig2 protein determines the cell fate of OPCs. The gray 
color represents Olig2 protein in either nucleus or cytoplasm. As the figure shows, Olig2 
localized in the nucleus will induce OPCs to differentiate into OL lineage cells. Instead, 
cytoplasmic translocation of Olig2 can lead the OPCs to undergo the astrocyte pathway.  
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Immunohistochemical analysis of OL and astrocyte lineage cells 
 
Figure 16. Immunohistochemical analysis of Olig2Nuc+ve/GFAP-ve cells (A, D), 
Olig2Nuc+ve/PDGFαR+ve cells (B, E), PDGFαR+ve/GFAP-ve cells (C, F) in coronal 
sections through the RCC (n=3). The images were obtained from CC of 6 month-old 
cuprizone (A, D), cuprizone recovery (B, E), and control (C, F) mice.  The white boxed 
area in ‘A’–‘C’ denote the portion of each image that is shown at higher magnification in 
‘D’-‘F’, respectively.  ‘D’ shows two Olig2Nuc+ve/GFAP-ve cells in the top center of the 
image (arrow).  ‘E’ shows an Olig2Nuc+ve/PDGFαR+ve cell in the center of the image 
(arrow).  ‘F’ shows a PDGFαR+ve/GFAP-ve cell on the left side of the image (arrow). 
The arrowhead in ‘A’ points out an Olig2Cyto+ve/GFAP-ve cell, in ‘B’ points out an 
Olig2Cyto+ve/PDGFαR+ve cell, and in ‘C’ points out a PDGFαR-ve/GFAP+ve astrocyte. 
bar (A, D) = 50 microns. 
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Histograms depicting the mean number of OL lineage cells in the RCC 
 
Figure 17. Histograms depicting the mean number (+/- SEM) of progenitor 
(PDGFαR+ve/GFAP-ve), OL progenitor (Olig2Nuc+ve/PDGFαR+ve), and OL lineage 
(Olig2Nuc+ve/GFAP-ve) cells in the RCC of 2 (A), 6 (B), 12 (C) and 16 (D) month-old 
control, cuprizone and cuprizone recovery mice (n=3). The two-way ANOVAs showed a 
significant main effect of phenotype (p<0.0001 for all four ages) as well as a significant 
interaction between phenotype and treatment (p<0.0001, p=0.02, p<0.0001 and p=0.004, 
respectively). There was also a significant main effect of treatment, but only at 12 months 
of age (p<0.0001). For all histograms, the brackets in color denote significant differences 
within a phenotype (e.g. Olig2Nuc+ve/GFAP-ve), whereas black brackets denote 
significant differences between phenotypes (Bonferroni’s post-test; significance level of 
p<0.05). 
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4.11 Changes in density of the astrocyte lineage after cuprizone-induced 
demyelination and three weeks recovery 
Astrocytes respond to tissue damage, thus any changes in astrocyte cell number after 
cuprizone or cuprizone recovery could be as result of cuprizone treatment or aging. With 
regard to astrocyte lineage cell, we focused on the immunostaining of Olig2/GFAP and 
PDGFαR/Olig2. Due to the functions of cytoplasmic Olig2 protein, we collected data of 
PDGFαR+ve/ Olig2Cyto+ve (Figure 18B) as astrocyte progenitor cells; 
Olig2Cyto+ve/GFAP+ve cells represented new-formed astrocyte (Figure 18A); and 
Olig2Cyto-ve/GFAP+ve cells that signified mature astrocytes. We analyzed the data by 
two-way ANOVA, as described previously. The independent variables were cell 
phenotype and the treatment. We focused on the comparison within the same age, instead 
of within all four ages.  
For 2 month-old mice, a huge increase in astrocyte progenitor cells (PDGFαR+ve/ 
Olig2Cyto+ve) was observed after cuprizone treatment (42 fold) and cuprizone recovery 
(32 fold) (Figure 18A). In addition, the cell number of newly-formed astrocytes was 
significantly increased after cuprizone treatment compared to the age-matched control 
(Figure 18A). However, none of difference was found in the cell densities of mature 
astrocyes (Figure 18A). It suggests that cuprizone treatment affected the cell densities of 
astrocyte progenitors and newly-formed astrocytes, but not mature astrocytes.  
With respect to 6 month-old mice, there was a significant increase in astrocyte 
progenitors after cuprizone recovery, compared to the age-matched control (Figure 18B). 
In addition, considerable increases in newly-formed astrocytes were observed after 
cuprizone treatment and cuprizone recovery (Figure 18B). Moreover, significant 
increases in cell densities were shown in mature astrocytes after cuprizone treatment and 
cuprizone recovery (Figure 18B). Thus, cuprizone treatment and cuprizone recovery 
affected the cell densities in all three cell types of astrocytes. 
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Similar to the 2 month-old mice, there were significant increases in astrocyte 
progenitors after cuprizone treatment and cuprizone recovery (Figure 18C). Treatment-
related differences were also seen in the cell number of newly formed astrocytes in the 
RCC of 12 month-old mice (Figure 18C). Compared to that of 6 months of age, there was 
no statistical difference in mature astrocyte cell density during cuprizone treatment and 
recovery (Figure 18C). Therefore, treatment-related differences were seen only in 
astrocyte progenitors and new-formed astrocytes, but not in mature astrocytes.  
In the RCC of 16 month-old mice, significant increases in astrocyte progenitors and 
new-formed astrocytes were only revealed after cuprizone treatment (Figure 18D). There 
were no considerable changes in cell densities in astrocyte progenitors and newly formed 
astrocytes after cuprizone recovery at the age ((Figure 18D). In addition, no changes in 
mature astrocytes were observed, during either cuprizone treatment or cuprizone recovery 
(Figure 18D). Thus, the cuprizone-related effects on cell density of astrocyte were 
confined to astrocyte progenitors and newly formed astrocytes.  
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Histograms depicting the mean number of astrocyte lineage cells in the RCC 
               
 
Figure 18. Histograms depicting the mean number of astrocyte progenitor cells, 
newly formed astrocytes, and mature astrocyte in the RCC of 2 (A), 6 (B), 12 (C), and 
16 (D) months old control, cuprizone treatment, and cuprizone recovery mice (n=3). 
The two-way ANOVA revealed a significant effect of treatment (p<0.0001) and 
interaction (p=0.009) in 2 month-old. There was also significant effects of phenotype 
(p<0.001) and interaction (p<0.0001) in 6 month-old mice. For 12 month-old mice, 
there were significant effects of treatment and interaction (p<0.0001), but no significant 
effect of phenotype. For 16 months old mice, there was a main effect of phenotype 
(p<0.0001) and a significant interaction effect (p=0.003). For all histograms, the 
brackets denote significant differences (Bonferroni’s post test, p<0.05). 
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V Discussion 
The efficiency of OL myelination and remyelination is decreased following aging. 
Significant research has demonstrated that the reduced efficiency of remyelination is due 
to the impaired OL progenitor recruitment and differentiation (Ando, et al., 2003; 
Franklin, et al., 2002; Peters, 2002; Rist and Franklin, 2008; Sim, et al., 2002). 
Furthermore, changes in transcriptional control has also been implicated . Transcriptional 
factors that up-regulate or prevent myelin gene expression were widely investigated 
(Franklin, et al., 2002; Sim, et al., 2002). Also, the expression of growth factors known to 
be important for oligodendrogenesis are delayed in older animals compared to young 
adults (Franklin, et al., 2002; Hinks and Franklin, 2000). All aspects have the possibility 
to contribute to impaired OL recruitment and delayed OPCs differentiation.  
In this study we focused on the recruitment and differentiation of OL progenitor 
cells. This research has provided some indication as to why the efficiency of myelination 
and remyelination were reduced in older animals. First, we showed an age-related 
reduction in OL progenitor cells recruitment, even though there was no age-related 
difference in the size of progenitor pool (Figure 14, 17). The cell densities of glial 
progenitors (PDGFαR+ve/GFAP-ve) and OL progenitor cells (PDGFαR+ve/ Olig2Nuc+ve) 
appeared to remain fairly constant across all 4 ages of control mice. Second, there was no 
significant increase in glial progenitors and OL progenitors after cuprizone treatment in 
the adult (6 months) and aged (12, 16 months) mice. In contrast, there were significant 
increases in cell densities of astrocyte progenitor cells after cuprizone treatment. Third, 
we found significant increases in cell densities of newly-formed astrocytes 
(Olig2Cyto+ve/GFAP+ve) in 2 to 16 months old mice after cuprizone treatment (Figure 
18). In addition, the translocation of Olig2 from nuclei to cytoplasm showed in our data, 
implies cell fate change after cuprizone treatment in older mice. Fourth, with respect to 
TFs Olig2 and Nkx2.2, there was an age-related reduction in Olig2 expression in the 
control mice, while the expression of Nkx2.2 was significantly increased after cuprizone 
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treatment in older aged mice. Finally it would appear that between 12 and 16 months was 
the time point in aging mice that there is an age-related decrease of OL lineage cells in 
control mice.  
With respect to the reduced myelination efficiency in older animals, we compared 
the progenitor cell pools within 4 ages of control mice. No significant difference was 
found in the aged control mice compared to the younger age. In control mice, the cell 
densities of both glial cell and OL progenitors were fairly constant. Thus, we confirmed 
that this decreased efficiency is not due to a change in the progenitor pool of these cells. 
In addition, the density of glial progenitors only increased significantly in 2 months 
cuprizone mice compared to the age-matched control (Figure 17). This was also 
confirmed in another study which employed a tamoxifen-inducible Cre-ER under the 
control of Olig2 promoter gene as well as a ROSA-EGFP reporter to trace the fate of 
Olig2+ve cells (Islam, et al., 2009). Furthermore, in mice at 12 and 16 months of age, we 
found the density of glial progenitors in cuprizone mice was only 36% and 41% (p<0.05), 
respectively, compared to the cell density seen in the 2 month-old cuprizone mice. 
According to Rivers, et al., (2008), the cell cycle of glial progenitors is only about one 
week. Hence, 6 weeks of cuprizone treatment provided sufficient time to generate glial 
progenitor cells. 
The study of Rivers et al. (2008) demonstrated that about one-third of mature OLs 
present in the RCC of 8.5 month-old mice had been formed de novo between 1.5 and 8.5 
months of age. Thus, there is accumulation of OLs starting from the younger age until at 
least 8.5 months of age in mice. From my project, it was not surprising to find that the 
densities of OL lineage cells in 12 months control mice were significantly higher (p<0.05) 
than that in 2 and 6 month-old mice. However, the cell density were down at 16 months 
of age. These findings suggest that OLs may continue to generate up to 12 month-old in 
the RCC of mice, and start losing the cell population sometime prior to 16 months of age. 
To our knowledge, no one has assessed OL cell numbers past 16 months of age. 
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In spite of the increased numbers of OL lineage cells that were present in the 12 
month-old control mice, there was a 3.1- and 2.1-fold decrease in MOG and CGT gene 
expression, respectively, compared to 2 months control. However, CGT gene expression 
did not show a significant difference between 2 and 6 month-old mice. Data suggests that 
12 months is likely to be the time point for OL progenitor cells to begin to lose their 
differentiation capability. Although MOG gene expression exhibited significant increases 
after cuprizone treatment and cuprizone recovery at 12 and 16 month-old mice, 
immunohistochemical studies failed to show a recovery of myelin in the RCC. It can be 
speculated that this is probably because the ability of genes to translate into proteins was 
reduced with age. Combined with the results of decreased number of OL lineage cells 
after 12 months, It would appear that 12 months is the key point for aged mice to lose the 
ability of myelination and remyelination.  
Data also show that the expression of TFs changed with age. We found that Nkx2.2 
expression showed an age-related increase, whereas Olig2 expression was down-
regulated in the control mice. Olig2 is expressed at all stages of OL lineage cells. The 
locations of Olig2 direct the cell fate determination of OPCs. Especially, when Olig2 is 
located in the nucleus, it functions as transcriptional activator to promote the 
differentiation and maturation of OLs (Nicolay, et al., 2007). On the other hand, Nkx2.2 
is believed as a transcriptional repressor in OL lineage cells during normal aging and 
response to demyelination lesions. Particularly, Nkx2.2 represses genes associated with 
differentiation and maturation of OLs (Tochitani and Hayashizaki, 2008; Wei, et al., 
2005). Researches have indicated that Nkx2.2 TF repress myelin gene expression 
(Gokhan, et al., 2005; Wei, et al., 2005). In addition, after down-regulation of Nkx2.2, 
OL lineage cells express a myelinating phenotype (Nicolay, et al., 2004). Furthermore, 
expression of Nkx2.2 is significantly decreased in terminally differentiated OLs, and the 
knockdown of Nkx2.2 results in enhanced OL differentiation (Tochitani and Hayashizaki, 
2008 ).  
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It is possible that increased expression of Nkx2.2 contributes to the fate choice of 
glial progenitors to differentiate into astrocytes, directly or indirectly. Sun et al. (2003) 
reported there are both cooperative and cross-repressive interactions between Nkx2.2 and 
Olig2. However, the physical interaction between these two TFs was not sufficient for 
OL development. Hence, the cross-repressive interaction between these TFs might be 
altered during normal aging and in response to CNS demyelination in older mice. 
Therefore, the alteration of this interaction may play a significant role in impeding the OL 
progenitor cells to respond to the cuprizone treatment in the older mice. Indeed, we found 
higher expression levels of Nkx2.2 in 12 and 16 month-old mice.  
Our use of the cuprizone model on mice as old as 16 months of ages has 
demonstrated the tissue of the CC retains the capacity to generate new OLs even in mice 
as old as 16-month old. However, the cell densities of OL lineage cells are drastically 
reduced in the RCC of 12 and 16 month-old mice after cuprizone recovery. This is 
evidence of insufficient generation of new OLs to replace those lost due to the cuprizone 
treatment. This is likely because the cell fate the OPCs choose to differentiate is into 
astrocytes and not OLs. The data show an increased percentage of astrocyte progenitors 
in total glial cell progenitors, as well as in the increased cell densities after cuprizone 
treatment and cuprizone recovery mice in 12 and 16 month-old mice. Other researchers 
have demonstrated an increased number of glial progenitors in response to CNS injury 
(Cassinai-Ingoni, et al., 2006); Magnus, et al., 2007).  Data from my thesis shows an 
increased possibility of Olig2 expression in cytoplasm of glial progenitors in aged mice, 
allowing these progenitors to differentiate into astrocytes (Setoguchi and Kondo, 2004). 
A recent report (Islam, et al., 2009) showed no increase in the percentage of 
GFAP+ve/GFP+ve cells in the external capsule of 8-10 weeks old cuprizone mice. We 
also confirmed that there was no significant change in mature astrocytes in the 2 month-
old cuprizone mice. We quantified the cell densities of astrocyte lineage cells, including 
astrocyte progenitors, newly-formed astrocytes, and mature astrocytes. The cell densities 
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of newly-formed astrocytes were higher in the RCC of mice after cuprizone treatment, 
compared to the age-matched control. In addition, there were also more astrocyte 
progenitors in the RCC in response to cuprizone-induced demyelination.  
In conclusion, our findings provide some insight into why there is an age-related 
decreased efficiency of myelination and remyelination. The size of progenitor cell pool 
seems to remain fairly constant up to 16 months of age. However, the cells preferably 
differentiate into astrocyte lineage as opposed to OL lineage cell, starting at 6 months of 
age. TFs Nkx2.2 and Olig2 may be involved in this progress. The age-related increase of 
Nkx2.2 gene expression would certainly impede the differentiation of progenitors into OL 
lineage cells. In addition, the cytoplasmic translocation of Olig2 TF would facilitate their 
differentiation into astrocytes. Hence, a first step in improving remyelination efficiency in 
older animals may require both a reversal of age-related increased expression of 
transcriptional repressor Nkx2.2 and preventing the cytoplasmic translocation of Olig2.  
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VI Future directions 
In the present work, I investigated expression levels of myelin-related genes as well 
as some critical TFs, which are involved in OL lineage cells’ differentiation and 
maturation. The data collected from immunohistochemistry and qRT-PCR is useful for 
interpreting the changes in OL proliferation and differentiation during aging, as well as 
providing clues to functions of OL-specific TFs involved in the cell fate determination of 
OPCs. Our studies showed that 12 months of age in mice appears to be a critical time 
when mice are capable of remyelination following a demyelinating lesion after which the 
remyelinating ability declines. In mice of 12 months of age, MOG and MBP 
immunostaining after cuprizone recovery did not show as good a recovery as mice of 
younger age. As well, the gene expression levels of Olig2 and Nkx2.2 showed significant 
differences, beginning at 12 months of age. It is possible that the changes in gene 
expression of TFs may affect recruitment of OPCs from the glial progenitor pool. In 
addition, gene expression level of PDGF?R also showed a significant increase after 
cuprizone treatment only in the 12 month aged mice, indicating that an age related change 
in responsiveness is occurring then. Consequently, the complex interaction between OL-
specific genes and TFs will be an important area of further study especially in the context 
of aging. Gain-of -function or loss-of-function approach may help to investigate the main 
effectors of aging.  
My findings implicate TFs Olig2 and Nkx2.2 as important components of the 
transcriptional control network that may contribute to the age-related switch in fate 
choice of the PDGF?R+ve progenitor cells into OLs. Hence, control of gene expression 
of the TFs Nkx2.2 and Olig2 would be the first step in improving the differentiation of 
those progenitor cells into OLs, and therefore limit the extent of demyelination that can 
occur during normal aging and indeed improve remyelination efficiency in older animals. 
Sun, et al., (2003) reported that there are both cooperative and cross-repressive 
interactions between Nkx2.2 and Olig2, with the protein-protein interaction depending on 
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the homeodomain and the bHLH domain of each TF respectively.  However, Sun et al., 
(2003) demonstrated the physical interaction between the two TFs was not sufficient for 
OL development, although it is possible that the cross-repressive interaction between two 
TFs may be altered during normal aging and in response to CNS demyelination in the 
older animals. If this were the case, then this altered interaction could play a significant 
role in impeding the OPCs response to normal aging and to cuprizone treatment. For 
further studies, both in vivo and in vitro experiments could be used to test the interaction 
between Olig2 and Nkx2.2. CG4 cell is one of the cell lines that is widely used to 
investigate the OL development and differentiation in vitro (Todorich, et al., 2008). 
Vectors carrying Nkx2.2 or Olig2 genes can be used to upregulate expression or iRNA 
can be used to down-regulate Nkx2.2 or Olig2 to determine what role the TFs have on 
CG4 oligodendroglial differentiation and development. These experiments would also be 
used to determine impact of manipulating expression of one TF such Olig2 and 
measuring its effect on Nkx2.2 and vice versa to determine if relationship existed 
between these genes during OL differentiation or in OL cell fate determination. For the in 
vivo study a traditional gene knock-out strategy using homologous recombination can be 
used if the loss-of function of the gene is not lethal. However the Cre/loxp strategy may 
be better suited if a controlled conditional deletion of the gene is required in cases when 
the deletion of gene is lethal as is the case for Olig2 (Ono, et al., 2008; Masahira, et al., 
2006). In the Cre/loxp strategy, the gene of interest is flanked by loxp sites which are 
recognized by the enzyme cre and in a controlled manner can be used to delete the gene 
between the loxp sites at any time in the aging animal after treatment with a drug such as 
tamoxifen that can induce this process (Ono, et al., 2008; Masahira, et al., 2006). 
Cre/loxp strategy would be a good way to investigate the interaction between Olig2 and 
Nkx2.2 in adult aging mice in vivo. 
My findings also reveal the possibility of OPC differentiation into astrocytes in older 
animals and can contribute to further investigations in diseases, such as MS and AD 
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(Connor, 2004; Kahle, et al., 2009; Lindsberg, et al., 2010).The ratio of OLs vs. 
astrocytes may provide clues to the mechanism(s) involved in these diseases. The 
increased ratio of astrocytes to OL may induce mental diseases (section 2.3). In future 
studies that focus on those diseases it may be possible in animal models to compare the 
cell density of astrocytes between young and old animals. 
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